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Chromatographic methods were developed capable of separating and quantitating 
siRNA, lipids, and their potential breakdown products due to oxidation or hydrolysis.  
Such methods are essential to developing lipid nanoparticles (LNPs) as a formulation 
delivery system for siRNAs.  Separation of siRNAs was achieved using ion-pair 
reversed-phase liquid chromatography.  Part 1 of the thesis describes the development of 
an ion-pair reversed-phase HPLC method for the separation of closely related 
stereoisomers of a chemically modified siRNA duplex.  A systematic evaluation of key 
chromatographic parameters showed that a BEH C18 column with sub-2 μm particle size, 
coupled with the use of triethylammonium acetate as the ion-pair reagent and acetonitrile 
as the strong solvent of the hydro-organic mobile phase, achieved baseline resolution of 
siRNA stereoisomers and their desulfurization products.  A high column temperature, 
creating a denaturing condition for siRNA, is critical to the separation of stereoisomers.  
An aprotic organic modifier, such as acetonitrile, can effectively disrupt the hydrogen 
bonding interaction between the duplex and enable the separation of stereoisomers by 
promoting hydrophobic interactions between the C18 stationary phase and the 
stereoisomers.      
Part 2 of the thesis expands the utility of the ion-pair reversed-phase liquid 
chromatography to include a simultaneous separation of the main lipid components of an 
xxi 
 
LNP system.  Ion-pair reversed-phase separation conditions were developed that can 
reduce the retention gap between siRNAs and lipids that have significant differences in 
their physical and chemical properties.  Studies showed that a BEH phenyl column could 
significantly retain siRNA due to a combination of both hydrophobic and π - π 
interactions.  In contrast, the lipids experienced a reduced retention with the phenyl 
column, a key advantage attributed to the presence of a short alkyl chain component in 
the stationary phase compared to octyl- or octadecyl-derivatized silica.  While the ion-
pair reagents had virtually no impact on the separation of the lipids, the retention times of 
the siRNAs showed a quantitative correlation with the structure of the ion-pair reagents 
in the mobile phase.  The chromatographic separation conditions with a phenyl stationary 
phase, particularly with dibutylammonium acetate as the ion-pair reagent, markedly 
reduced the retention gap between the siRNAs and the lipids, achieving a baseline 
resolution of a complex matrix containing five siRNAs and six lipids in a 20-minute 
gradient elution method.     
Finally, the ion-pair reversed-phase method was applied to the degradation 
products of a model siRNA system.  Stress testing showed that the model siRNA 
developed minimal hydrolysis products at neutral pH.  This indicated the importance of 
chemical modification at the 2’-position in the ribose unit of siRNA molecules.  In 
contrast, the siRNA was prone to oxidation by hydrogen peroxide, with or without trace 
levels of a transition metal, and to oxidation by a radical initiator.  Desulfurization and 
phosphodiester strand scission were the likely main degradation pathways contributing to 
the observed oxidative reactivity.       
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 Chapter 1: Introduction to HPLC 
 
1.1       A brief history of HPLC  
 
Chromatography refers to a set of separation techniques where the components of 
a mixture are separated due to their different distribution coefficients between two 
immiscible phases.  The term “chromatography” was first introduced in 1905 by a 
Russian botanist, Mikhail Tswett.  He reported the separation of different plant pigments 
with glass columns packed with calcium carbonate. 
1
 Although Tswett is often considered 
as the father of modern chromatography, the concept of separating mixed components 
based on adsorption and desorption between two phases predated Tswett’s discovery.  A 
survey of earlier literature by Herbert Weil and Trevor Williams 
2
 showed that, as early 
as 1897, D.T. Day had demonstrated the fractionation of hydrocarbon in petroleum based 
on a differential adsorption process in packed columns. 
3
  
After Tswett’s initial discovery of chromatography, his work faded into obscurity 
until early in 1940 when Martin and Synge introduced partition chromatography.  Martin 
and Synge also developed the theory pertaining to liquid chromatography and correctly 
predicted that separation efficiency could significantly improve with small packing 
particles under high pressure. 
4,5
 Martin and Synge’s seminal work ushered in the dawn 
of modern liquid chromatography, and the remarkable contributions earned them the 
Nobel Prize in Chemistry in 1952.  
Following the ground-breaking work by Martin and Synge, Calvin Giddings 
6
 and 
Josef Huber 
7
 further proved in theory that LC could achieve high efficiency with 
columns packed with particles of less than 150 μm, when operated at high pressure to 
increase mobile phase linear velocity.  In the late 1960s, significant progress was made to 
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translate the theoretical potential of LC into practical applications.  Jack Kirkland and 
Csaba Horvath applied pellicular stationary phase (with 40 μm in diameter) for liquid 
chromatography, 
8,9
 achieving comparable efficiency as gas chromatography.  This work 
marked the true beginning of modern liquid chromatography.  The first commercial 
HPLC system was introduced in 1968 by Waters 
10
, and the technique emerged as an 
essential analytical tool around 1972 when columns packed with less than < 30 µm 
became available. 
11,12
 The speed and efficiency of HPLC system continued to improve 
with the introduction of even smaller particles,
13
 which ultimately led to the development 
of UHPLC system. 
14
  
As researchers explored packing materials with very small particles, they began to 
encounter the pressure-induced heat formation in the mobile phase, causing additional 
band broadening, which imposed an upper limit on the particle size and pressure for 
HPLC separation. 
15,16 
This technical issue was resolved by Jorgensen, who applied 
capillary HPLC column for ultra-pressure separation, where the heat transfer is more 
efficient than in the conventional column. 
17
 Ultra-high performance separation was 
finally achieved with the introduction of sub-2 μm particles in columns with a narrow 
outer diameter, coupled with an improvement in HPLC hardware to minimize extra-
column band broadening.
18
  Extra-column band broadening is all the processes outside 
the column that increase the width of chromatographic peaks.  The first commercial 
UHPLC system was introduced in 2004, which marked another important milestone since 
the initial discovery of “chromatography” almost a century ago. 19   
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1.2       HPLC theory and principles 
1.2.1    Key factors impacting chromatographic resolution 
The purpose of a separation is to resolve some or all of the components from each 
other in a matrix.  The separation of two bands can be modulated by changing the 
experimental conditions.  The resolution (Rs) is often used to describe the extent of the 
separation between two species 1 and 2, and it is related to three chromatographic 
parameters, the retention factor (k), selectivity (α) and plate number (N).  To establish the 
relationship between Rs and k, α and N, we first define the resolution of two solute zones, 
which is expressed in Eqn. (1.1)  
                                                                                                   (1.1) 
where tR is the retention time and w is the width of each peak.  The retention time (tR) is 
the amount of time a compound spends on the column after it has been injected.  The 
peak width is associated with the extent of a solute-zone, which is also related to the plate 
number as defined in (1.2).  σ is the standard deviation of the solute zone and can be 
measured from the peak width at baseline (w = 4σ), assuming a Gaussian distribution  
                                                                                                                 (1.2) 
The retention factor measures the amount of time the solute spends in the stationary 
phase compared with time spent in the mobile phase and is expressed by Eqn. (1.3), 
where t0 is the retention time of non-retaining species.  The retention factor can also be 
expressed as a mass-based equilibrium constant and can thus be seen to be independent of 
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column length, radius and flow rate (Eqn. 1.4).  NS and NM refer to the number of moles 
of the solute in the stationary phase and mobile phase, respectively.  
                                                                                                              (1.3) 
                                                                                                                    (1.4)  
The selectivity (α) is the ratio of the retention factors of two solutes, as defined in Eqn. 
(1.5).  The selectivity or relative spacing of the two analytes can be varied by changing 
the stationary and mobile phases.  
                                                                                                                   (1.5) 
Lastly, the resolution (Rs) can be expressed in Eqn. (1.6) 
20
 with N, k and α as key 
variables.  
                                                                           (1.6) 
The equation shows that separation resolution is impacted by plate number (N), 
the selectivity factor and retention factor.  Partial derivatives of the resolution equation 
further revealed that the impact of the three fundamental variables on resolution 
decreases in the following order: selectivity > retention factor > plate number.  This order 
suggests that for any separation method development, one should begin with the selection 
of column type and mobile phase composition, which has a direct impact on selectivity.  
The next step involves the optimization of the retention factor with adjustment of the 
mobile phase composition as a function of time.  Lastly, the plate number can be 
improved by optimizing the flow rate, particle size, and the column dimensions.  
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1.2.2    Fundamental principles of band broadening and zone separation  
Equation (1.6) 
20 
shows the relationship between resolution (Rs) and key 
chromatographic parameters, thus providing a general rule of thumb for HPLC method 
development.  To systematically improve separation speed and efficiency, we need to 
understand band broadening and zone separation at a molecular level.  A well-established 
theory exists that relates band broadening and zone separation to fundamental parameters, 
such as molecular diffusion coefficient, the partition coefficients of the analytes between 
the two phases, and the physical properties of the packing material in the column (particle 
size, porosity, etc.). 
1.2.2.1 Column contributions to band dispersions and Van Deemter equation 
As an analyte travels through a packed column, multiple sources contributed to 
band broadening, including eddying (A), i.e., a bulk diffusion by mean of multiple paths 
taken by the solute, longitudinal dispersion (B) and resistance to mass transfer (C) in both 
the mobile and stationary phases. 
6,21,22
  For a uniformly packed column, the variance due 
to multiple paths taken by the solute is described as in (1.7).   
                                                          σA
2
 = 2λdpL                                                      (1.7) 
where λ is a constant (0.5 to 1) that is related to the packing structure, dp is particle 
diameter, and L is the column length.  Large and irregular particles will cause significant 
band broadening.  
The random motion of molecules along the separation axis in the mobile and 
stationary phases also leads to band broadening; this is called longitudinal diffusion.  The 
variance due to diffusion in the mobile phase and stationary phases is calculated as 
follows: 
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                                                                                          (1.8) 
                                                                                           (1.9) 
where DM and DS are the bulk diffusivity coefficients in the mobile phase and stationary 
phase, respectively.  γM and γS stand for the tortuosity factors in the mobile and stationary 
phases, respectively.  u is the linear velocity of the mobile phase.  The equation (1.9) 
suggests that the variance contribution to band broadening in stationary phase increases 
with retention factor as the analyte will spend more time diffusing in the column.  This 
explains why late eluting peaks tend to be broader than the earlier eluters.    
As an analyte migrates through a packed column in a stream of the mobile phase, 
the solute tends to remain in its transport path due to inertial forces, or its resistance to 
mass transfer.  The flow pattern in a packed column invariably is parabolic, meaning flow 
in the center of the channel tends to move faster than flow closer to the channel boundary 
due to reduced frictional force as the boundary is approaching.  The resistance to mass 
transfer, coupled with a differential flow rate across the column radius, leads to zone 
broadening during separation.  For laminar flow in a packed column, the variance 
contribution to band broadening in mobile phase can be described as: 
                                                                                               (1.10) 
For a given linear velocity, broadening due to resistance to mass transfer is more 
significant for liquid chromatography than in gas chromatography since the D term is in 
the denominator and it is higher in the gas phase than in the liquid phase.  Typically, 
however, the reduced linear velocities, i.e., the linear velocities relative to the 
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column/particle dimensions are similar, and in those instances the relative contribution to 
resistance to mass transfer to overall band broadening in GC and LC are comparable.   
The total variance contribution to band broadening that occurs within the column is   
                                            σtotal
2
 =  σA
2 
+  σB
2
M + σB
2
S + σC
2
S                                 (1.11)                                            
Equation (1.12) can be further simplified based on equations (1.2) and (1.7) to (1.11).   
                                                       H = A + B/u + Cu                                              (1.12)  
where H is the plate height, the column length divided by theoretical plate number (N).  
The A term represents the eddy diffusion, and B and C terms are related to longitudinal 
diffusion and resistance to mass transfer, respectively, in both mobile phase and 
stationary phases.   
Equation (1.12), also called the van Deemter equation, shows the change of plate height 
as a function of the linear velocity of the mobile phase.  For a given mobile phase 
composition and stationary phase, the resolving power is at maximum for a column at an 
optimum linear velocity   
                                                          uopt = (B/C)
1/2
                                                 (1.13) 
The van Deemter equation also highlights a significant impact of particle size on 
plate height.  As the particle size decreases, the minimum plate height occurs at a higher 
velocity.  This sets up the theoretical foundation for UHPLC technique where the 
resolving power is improved with sub-2 μm particles under high pressure.   
1.2.2.2 Fundamental principles of solute-zone separation  
In addition to the influence of theoretical plate number (N), retention factor and 
selectivity also impact the resolution (Rs).  The thermodynamic information provides a 
mechanistic framework for the molecular interaction between the solute and the mobile 
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phase and stationary phase, which are related intrinsically to retention factor and 
selectivity.  In chromatography, the free energy associated with partitioning of the solute 
between the mobile phase and the stationary phase is related to molar enthalpy (H) and 
entropy (S).  The enthalpy is attributed to the molecular interaction between the solute 
and the two phases, and entropy is related to the disorder of the system.  The free energy 
is also related to the thermodynamic equilibrium constant for the solute, which is 
partitioning between the two phases, as shown in eqn. (1.14). 
23
 
                                                 Ln K = 
−∆𝐺
𝑅𝑇
 = 
−∆𝐻
𝑅𝑇
  + 
∆𝑆
𝑅
                                            (1.14)   
The equilibrium constant K is the ratio of solute activity in the mobile phase and 
stationary phase, which is related to the retention factor via eqn. (1.15).  
                                                                                  (1.15) 
where aS and aM are the respective activities of the solute in the stationary phase and 
mobile phase, and β is the ratio of the volumes of the mobile phase (Vm) and the 
stationary phase (Vs).  Eqn. (1.14) can be written as eqn. (1.16) which relates the 
retention factor to the thermodynamic parameter of the partitioning process.  
                                            Ln k = 
−∆𝐻
𝑅𝑇
  + 
∆𝑆
𝑅
  - lnβ                                           (1.16)  
1.3       HPLC methodology 
There are several separation techniques within the framework of HPLC.  Most of 
the methods explored the fundamental physical and chemical differences between the 
molecules.  
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1.3.1    Normal-phase liquid chromatography 
In normal phase liquid chromatography (NPLC), the stationary phase is more 
polar than the mobile phase.  The stationary phase can be unmodified polar inorganic 
adsorbents, such as silica, alumina, or zirconia, or a bonded phase on a silica support.  
The mobile phase is a mixture of non-polar organic solvents, like hexane, heptane plus 
isopropanol alcohol (IPA), without water.  The main retention mechanism is an 
adsorption/desorption process, where the adsorption sites are the silanol groups on 
unmodified silica or polar groups, such as cyano, amino, or diol for bonded silica.  The 
retention behavior is governed by the Soczewinski equation (1.13) 
24
 
                                                       Log k = C - N log XB                                                           (1.13) 
where C and N are constants for a given analyte and XB is mole fraction of B solvent in 
the mobile phase.  N also represents the number of polar groups in the analyte.  
Regardless of the mobile phase or stationary selected, the retention time of normal phase 
separation always increases as the mobile phase polarity decreases.  For a given 
separation condition, the retention time increases as the polarity of the analytes increases.    
Although NPLC is less popular than reversed-phase liquid chromatography 
(RPLC), it finds important applications in separating very polar analytes, such as 
carbohydrates, where retention and resolution on a reversed-phase column are 
challenging to achieve.  Normal phase separation often achieves superior separation of 
positional isomers and diastereomers.
.25,26,27,28 
1.3.2    Reversed-phase liquid chromatography  
Majority of the chromatography separation relies on the reversed-phase 
methodology, making this technique by far the most important of all.  Reverse-phase 
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liquid chromatography (RPLC) is often the first choice for normal samples.  The 
separation technique applies to a broad range of sample matrices, including polar and 
non-polar small molecules, achiral isomers, chiral isomers, and biomolecules.  The 
mobile phase, consisting of a mixture of water and organic solvents of different polarity, 
is more polar than the stationary phase, typically a silica support modified with C8 or 
C18.   The separation of a mixture of solutes is based on the partition mechanism.
29,
 
30, 31
 
As the solutes migrate through the reversed-phase column, the non-polar samples will 
preferentially partition into the hydrophobic stationary phase as opposed to the mobile 
phase;  therefore the non-polar solutes are retained more strongly on the column.  For a 
given mobile phase condition, the analytes will be separated based on their 
hydrophobicity.   
Key experimental factors impacting RPLC retention include the mobile phase, the 
stationary phase, and the temperature.  In terms of mobile phase, solvent strength 
profoundly influences the retention of the analyte.  At a first approximation, log k has a 
linear relationship with the percentage of mobile phase B (the strong solvent), as shown 
in Eqn. (1.14). 
32
 
                                                      log k  = log kW – SϕB                                           (1.14)  
Where kw is a theoretical value of k when the mobile phase is 100% water, S is a constant 
and ϕB is the volume fraction of the mobile phase B.   Common organic solvents used for 
RPLC separation include methanol (MeOH), acetonitrile (ACN), tetrahydrofuran (THF) 
and 2-propanol.  These solvents are all somewhat polar.  The solvent strength (or 
hydrophobicity) increases in the order of MeOH < ACN < THF < 2-propanol, with 2-
propanol being the most hydrophobic. 
33,34
 RPLC column is another variable controlling 
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the retention of the analytes.  Most of RPLC separations use silica-based columns to 
which a hydrocarbon is bonded.  The chemistry and concentration of the bonded phase, 
as well as the surface area all impact the retention characteristics of the analytes.  For 
non-polar and non-ionic species, the retention increases in the following order for 
bonded-phase silica column: Cyano < C4 < C8 < C18. 
35,36
  
1.3.3    Ion-pair chromatography 
Ion-pair chromatography refers to a separation technique that uses organic or 
inorganic ionic additives, introduced into the mobile phase to achieve adequate retention 
of charged analytes (Figure 1.1).  As the mobile phase runs through the column, the 
concentration of the ion-pair reagent will reach equilibrium between the stationary phase 
and the mobile phase.  Two co-existing mechanisms contribute to the retention of the 
ionic solutes.  The first is the formation of an ion-pair in solution, followed by 
partitioning of the ion-pair into the stationary phase.  The ion-pair reagent can also 
partition directly into the stationary phase, forming a dynamic ion-exchange stationary 
phase to interact with the free ionic solutes via charge-charge interaction. 
37,38
 
 
 
                (a)           (b)                                                                                          
Figure 1.1 Schematic diagram of ion-pair chromatography retention 
(a) Retention of a positively charged analyte via charge-charge interaction with ion-
pair reagent partitioned into station phase.  
(b) Retention of ion-paired complex via partition into stationary phase 
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The manipulation of ion-pair chromatography shares many features with 
reversed-phase separation techniques, including the selection of mobile phase and 
stationary phase.  The only difference is that ion-pair chromatography incorporates 
ionizable or permanently charged additives in the mobile phase.  Similar to reversed-
phase chromatography, the retention in ion-pair chromatography is impacted by mobile 
phase composition, such as the solvent strength and pH of the mobile phase, and the 
chemistry of the bonded phase. 
39
  In addition, the types of ion-pair reagents, as well as 
their concentrations, have a significant impact on the retention time of the analytes.  For 
an ion-pair reverse-phase separation, the retention time of the analyte tends to increase 
with increasing hydrophobicity of the ion-pair reagent.  For a given type of ion-pair 
reagent, an increase in the concentration leads to a longer retention time for the analyte 
until it reaches a plateau due to saturation of the stationary phase with the ion-pair 
reagent.  Since an ion-exchange process is part of the retention mechanism for ion-pair 
chromatography, a high concentration of ion-pair reagent can reduce the retention time, 
and this is due to the competition of the counter ion (of the ion-pair reagent) with the 
analytes for interaction with the column.       
1.3.4    Ion-exchange chromatography 
Ion-exchange chromatography (IEC) is a branch of separation techniques that find 
most applications in the life sciences, such as the separation of biomolecules, including 
carbohydrates, amino acids, peptides and most importantly, oligonucleotides.   IEC is 
also useful in separating small and highly charged cations or anions.  IEC separations are 
performed on columns that are functionalized with cation or anion exchangers via 
covalent bonds.  Figures 1.2 and 1.3 show typical cation and anion exchange functional 
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groups.  The mobile phase typically consists of water, buffer, and inorganic salt.  
Retention is based on competition between the sample ions and mobile phase counterions 
(the dissociated product from the salt) for interaction with the stationary phase.   
Retention time in IEC can be varied by the type of the counterion and its concentration, 
as well as the pH and solvent strength of the mobile phase.  Different types of 
counterions have different charge densities that can impact the binding affinity to the ion 
exchange functional groups.  Counterions with a higher charge are more effective in 
displacing the analyte than those with a lower charge, leading to a shorter retention.  The 
relative ability of an ion to displace the analytes and to provide smaller values of 
retention factor k is in the following order:   
Anion exchanger: F
-
 < OH
- 
< acetate
-
 < Cl
- 
<SCN
- 
< Br
- 
< NO3
- 
< I
- 
>oxalate 
-2 
< SO2 
-2
 < 
citrate
-3
  
  
Cation exchanger: Li
+
 < H
+
 < Na
+
 < NH4 
+
 <K
+
 < Rb
+
 < Cs
+
 < Ag
+
 < Mg
2+
< Zn
2+
 < Co
2+
 
< Cu
2+
 <Cd
2+
 <Ni
2+
 < Ca
2+
 < Pb
2+
 < Ba
2+
 
 
 
The retention factor is related to the concentration of counterion via Eqn (1.15). 
40,
 
41
 
                                                       log k = a – mlogC                                                  (1.15) 
where a and m are constant for a given analyte, m is related to an absolute charge of the 
analyte, and C is the concentration of the counterion.  Other factors, including the ionic 
strength and pH of the mobile phase, also impact retention.  In general, as the ionic 
strength increases, the interaction between analyte and ion exchange functional group in 
the stationary phase is weakened, resulting in less retention.  As expected, the impact of 
pH on retention in IEC is associated with the pKa(s) of the analyte, if any, and the trend 
is opposite to that of RPLC due to different retention mechanism.   
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(a) SCX                                                          (b) WCX 
Figure 1.2 Cation-exchange functional groups 
(a): SCX = strong cation exchange; (b): WCX = weak cation exchange  
 
 
 
 
 
(a) SAX                                                          (b) WAX 
Figure 1.3 Anion-exchange functional groups 
(a): SAX = strong anion exchange; (b): WAX = weak anion exchange  
 
 
 
1.3.5    Size exclusion chromatography 
Size exclusion chromatography (SEC) separates molecules based on size and 
shape, making this technique the simplest form of chromatography.  The separation is 
performed on a passive stationary phase with porous particles, including inorganic silica 
or polymeric organic material.  The retention mechanism is a permeation process where 
the hydrodynamic radius of the molecule governs the extent of permeation into the pore 
15 
 
 
 
of the packing material.  Large molecules will spend less time inside the pores of the 
packaging material, therefore eluting with a smaller volume of the mobile phase.  In 
contrast, molecules of a smaller size can freely diffuse in and out the pores, exhibiting a 
greater retention volume.  The SEC partition coefficient is proportional to the fraction of 
the intra-particle (pore) volume that is accessible to the solute, as shown in Eqn. (1.16).  
42
 
                                                                                                    (1.16) 
Where VR, V0, and Vi are the retention volume of the analyte of interest, the interstitial 
volume, and the intra-particle volume, respectively.   The partition coefficient ranges 
from 0 to 1 with zero representing the solutes that can freely access the entire pore 
volume of the stationary phase, while a retention factor of unity refers to analytes that are 
too large and have no access to the intraparticle pore structure, being completely 
excluded from the pores.   
The main application of SEC is to measure the molecular weight distribution of 
the solute.  For an analyte with a partition coefficient between 0 and 1, the elution volume 
has a linear relationship to the molecular weight (Eqn. 1.17). 
                                                                                   (1.17) 
Since retention time in SEC is influenced by the hydrodynamic radius of the analyte, the 
technique is an important tool to study physical aggregation of the biomolecules, such as 
proteins and peptides. 
43
  Other applications include the determination of nanoparticle 
size and shape. 
44
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Chapter 2: Overview of small interfering RNA-based therapy, delivery technology 
and analytical characterization of lipid nanoparticle formulations  
 
2.1  RNA interference: mechanism of action and biologic significance 
 
RNA interference (RNAi) is a naturally occurring biological event in a cell’s 
cytoplasm where double-stranded (ds) RNA interferes with the expression of a specific 
gene.  It was first discovered by Fire and Mello in their seminal work to study the effect 
of exogenous ds-RNA on Unv-22 gene (encoded for myofilament protein) expression in 
C. elegans.
1
  The gene-silencing effect of small interfering RNA (siRNA) was further 
demonstrated in mammalian cells using synthetic siRNA (21 to 23 mers, Figure 2.1). 
2
 
RNA interference (Figure 2.2) begins with the breakdown of a long double-stranded 
RNA molecule by an enzyme called Dicer, forming a 21- to 23-mer small interfering 
RNA.  The short strand RNA binds RNA-induced silencing complex (RISC) and splits 
itself into single strands.  Following the cleavage of the sensing RNA single strand, the 
antisense RNA will selectively bind and degrade mRNA with a complementary sequence, 
achieving a gene silencing effect that can last for days to weeks.  RNA interference is an 
important biological process that allows cells to fight against viral attack or gene 
mutation.  The RNA interference (RNAi) mechanism is also implicated for controlling 
protein level in cells responding to various external stimuli.
3
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Figure 2.1 A generalized structure of a siRNA drug with the ribose sugars, 
phosphodiester bonds and bases (B).  
   
 
 
The phenomenon of RNA interference represents a fundamental tool to study 
gene function, and more importantly, it offers a novel approach to develop new 
therapeutics for treating a variety of diseases.  siRNA-based therapeutics have several 
advantages compared to gene therapy or protein or small molecule-based drugs due to its 
direct interference with protein translation, avoiding gene altering events that could occur 
with DNA-based drugs.  siRNA acts on mRNA, hence suppressing certain harmful  
proteins before they are made in the body.  Furthermore, siRNA is easy to design and can 
engage a broader range of disease targets than traditional therapeutics. 
4
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Figure 2.2 The mechanism of RNA interference 
 
RNAi machinery has provided new opportunities for treating diseases with 
significant unmet medical needs, such as cancer, autoimmune disorders, and viral 
infections.  The genetic nature of cancer implies that siRNAs, with complementary 
sequences to cancer genes, can directly target the tumor cells.  siRNA sequences loaded 
in lipid- or polymer-based nanocarriers showed early promise in suppressing the target 
genes associated with breast cancer, cervical cancer, liver cancer, lung cancer and 
prostate cancer. 
4
 Autoimmune disorders, such as rheumatic diseases, have complex 
pathogeneses, and the identification of the underlying genes responsible for inflammation 
and structure damage yielded promising siRNA therapeutic candidates. 
5
 RNAi-based 
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therapy is also uniquely suited to combat viral infections.  Standard treatment for HIV 
and hepatitis C virus often involves a cocktail of multiple drugs, and strict adherence to 
dosing regimen is vital to combat drug resistance due to viral mutation. 
6,7
 siRNAs 
targeting several gene products can reduce such mutations with a single injection.  The 
therapeutic effect can last for weeks and months owing to the catalytic nature of gene 
suppression by siRNA. 
8
   
Since the inception of siRNA-based biomedical research, there have been over 50 
clinical trials executed that focus on the safety and efficacy of more than 20 different 
siRNA sequences in humans. 
9,10,11,12, 13
 Early trials primarily relied on local delivery of 
siRNA to target tissues/organs.  The first siRNA clinical trial commenced in 2004 to test 
the safety and efficacy of Bevasiranib (a siRNA targeting vascular endothelial growth 
factor (VEGF) to inhibit retinal neovascularization) in age-related macular degeneration 
(AMD) patients.  The study was sponsored by Opko Health Inc., and it met primary goals 
for phase I and II.  The program was later terminated in phase III due to poor efficacy. 
12 
Quark Pharmaceuticals conducted the first clinical trial of QPI-1002 (I5NP), an uncoated 
siRNA, which targeted pro-apoptotic protein p53 in patients undergoing kidney 
transplantation.  A delivery vehicle is not needed since uncoated RNA is often 
accumulated in the kidney, the target organ for this therapy.  QPI-1002 (I5NP) is safe and 
well tolerated in patients, and it achieved sustained p53 suppression.  A phase II study is 
ongoing with results pending.  In 2008, Calando Pharmaceuticals initiated a phase I trial, 
which demonstrated for the first time the systemic delivery of siRNA (CALAA-01) via 
IV injection of siRNA containing nanocarriers.  CALAA-01 was intended for treating 
melanoma and specifically targeted ribonuclease reductase.  The study was later 
23 
 
terminated due to findings related to safety. 
14
 PRO-040201 (TKM-ApoB) was developed 
by Tekmira Pharmaceuticals using SNALP (stable nucleic acid lipid particle) delivery 
technology.  The drug was tested in patients with hypercholesterolemia and achieved a 
good safety profile.  Unfortunately, the development was later terminated due to an 
immune response likely triggered by the siRNA. 
9  
Despite setbacks in the earlier trials, 
several siRNA-based drug candidates have advanced into phase II/III.  ALN-TTR02 
(Patisiran) was developed by Alnylam Pharmaceuticals for treating TTR-mediated 
amyloidosis.  Based on encouraging phase I data in patients with transthyretin 
amyloidosis, the drug candidate is currently being evaluated in phase II/III for its long-
term safety and tolerability in a broader patient population.  TKM-PLK1 by Tekmira 
Pharmaceuticals, targeting polo-like kinase-1, is also being evaluated in Phase II trials for 
treating the solid tumor in the liver.        
2.2 siRNA delivery platforms 
With a properly designed siRNA sequence, RNAi machinery can be exploited to 
silence any gene in the body, opening a new frontier for developing personalized 
medicines.  Although developing siRNA into clinically viable therapeutics is promising, 
significant challenges remain.  Due to their size and negative charge, siRNAs cannot 
easily pass through a cell’s membrane.  Therefore, the safe and effective delivery of 
siRNA has been the biggest challenge for RNAi technology in addition to the toxicities 
related to off-target gene-silencing effects. 
15,16  
Local delivery of naked siRNA is 
possible for tissues that are external, such as ocular, pulmonary, colonic, epidermal, etc. 
9, 
12
  For broad applications, a systemic delivery of siRNA is critically needed as many 
target tissues can only be accessed via the bloodstream.  There are multiple challenges to 
24 
 
achieving the systemic delivery of siRNA. 
17, 18 
First is the enzymatic degradation of 
siRNA by endogenous nucleases. 
19
 The structural integrity of siRNA largely relies on 
chemical modification with protective groups or physical encapsulation using 
macromolecules, such as lipid or polymer.  In addition to maintaining chemical stability 
post-injection, the siRNA complex must navigate in the circulatory system without 
premature clearance due to kidney filtration, aggregation with serum proteins, and uptake 
by phagocytes.  Encapsulation of siRNA in lipid or polymer nanocarriers with 
engineering control of the size, shape, and surface charge significantly prolongs the half-
life of siRNA in blood.  The next challenge for siRNA delivery is permeation through the 
cell membrane, which proceeds through receptor-mediated endocytosis.  Endocytosis is a 
cellular process where the cells absorb molecules or substances from outside the cell by 
engulfing it with the cell membrane.  The process of endocytosis forms a membrane-
bound vesicle, also known as an endosome, inside the cell.  The size of the endosome 
varies according to the cell type.  For example, in HeLa cells, endosomes are 
approximately 500 nm in diameter when fully mature. 
20
  Once inside the cell, the intact 
siRNA is liberated from the delivery cargo and released into the cytoplasm to invoke its 
gene-silencing function.  Accomplishing this complex sequence of events requires the 
elegant design of an integrated delivery system, which includes the carriers (lipids or 
polymers), cell targeting ligands, and shielding ligands to avoid off-target interactions. 
21, 
22
 Many delivery systems have been explored in the past two decades, including siRNA-
containing lipid nanoparticles, siRNA polymer conjugate, or siRNA single chemical 
entities. 
23, 24, 25   
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2.2.1    Lipid-based delivery systems 
In an aqueous environment, lipids have the tendency to form unilamellar or 
multilamellar liposomes, where the lipid bilayers form a sphere with an aqueous core.  
The liposome-based technology was first reported 30 years ago for the delivery of DNA 
and RNA.
26,
 
27
  The technology was later adopted for siRNA delivery with some 
modifications due to differences between DNA and siRNA in size, charge, and site of 
action.  Figure 2.3 shows a typical structure of a siRNA-containing lipid nanoparticle 
(LNP), with the particle sizes less than 100 nm.  The LNP is also referred as a unilamellar 
vesicle that is composed of a lipid bilayer.  siRNA is encapsulated in lipid bilayers, which 
consist mostly of cholesterol and cationic lipids.  The lipid bilayers also contain as a 
minor component, the PEGylated short-chain lipid, which is decorated on the bilayer 
surface.  The LNP enters the cell in a two-step process: a receptor (anchored on PEG tip) 
– mediated endocytosis, followed by endosome escape and release of siRNA into the 
cytoplasm.  The primary mechanism for cell uptake of a liposome is the fusion of a 
multilamellar lipoplex with the cell membrane as shown in Figure 2.4.  The cationic 
lipids are the most important components of LNPs for modulating the cell uptake of 
siRNA.  They directly influence siRNA encapsulation efficiency and the particle size and 
surface charge of LNPs, which are critical parameters for siRNA delivery to cell 
cytoplasm.
28
  The unsaturated hydrocarbon chain in the lipids, as well as the pH-
dependent charge density of the lipid’s headgroup, is responsible for the escape of siRNA 
from the endosome (or the rupture of endosome membrane).  The PEG group decorated 
on the LNP surface can mitigate the absorption of serum proteins, which can deactivate 
cell penetration of LNP.  The PEG group also improves the LNP’s physical stability in 
26 
 
systemic circulation upon IV injection, preventing particle aggregation in plasma.  Lastly, 
the PEG moiety can help LNPs to evade the immune system and avoid premature uptake 
by phagocytes. 
29, 30 
 
 
Figure 2.3 siRNA-containing lipid nanoparticles with surface modification with PEG  
polymers 
 
 
 
 
 
Figure 2.4 Schematic representation of the fusion of a multilamellar small interfering 
RNA lipoplex with the cell membrane.  The positively charged lipid bilayer adsorbs to 
the negatively charged surface of the cell, resulting in either an endocytosis process or by 
fusion of the lipoplex with the cell membrane, thereby releasing the nucleic payload into 
the cytosol.  During the process, the lipid membrane is stressed and lipids are freed to the 
intracellular and extracellular compartments. 
25 
 
 
 
2.2.1.1 Cationic lipids as carriers for siRNA delivery  
 
The majority of siRNA delivery vehicles employ cationic lipids as the carriers.  
Cationic lipids were originally used in stable nucleic acid lipid particle (SNALP) 
27 
 
formulations for DNA and RNA delivery in the 1980s. 
16
 The cationic lipid associates 
with negatively charged siRNA through electrostatic interactions, forming a complex 
known as lipoplex.  The lipoplex has a multilamellar structure with positively charged 
lipid bilayers separated by negatively charged siRNA sheets.  Studies have shown that 
cationic lipids, such as DOTAP (1,2-dioleoyl-3-trimethylammonium propane), can 
effectively encapsulate siRNA, forming liposomes that can interact with a negatively 
charged cell membrane to deliver siRNA into the cytoplasm. 
31
  The high permeability of 
liposomes through the cell membrane using early-generation cationic lipids did not 
translate into a high percentage of gene knockdowns due to poor endosome escape of the 
siRNA. 
32
  A combinatorial library of lipid-like molecules was generated for the 
systematic evaluation of siRNA delivery efficiency. 
33
 The screening efforts identified 
several novel cationic lipids capable of promoting the efficient delivery of siRNA both in 
vitro and in vivo.  A rational design of cationic lipids was proposed by Semple and his 
team based on the hypothesis that the structure of a cationic lipid impacts its interaction 
with naturally occurring anionic phospholipids in the endosomal membrane. 
28
 An ion-
pair event triggers the formation of a non-bilayer structure, a precursor for membrane 
disruption and endosome escape.  The structure and activity of a series of cationic lipids 
(Figure 2.5) were investigated to understand the impact of the alkyl chain, linker, and 
headgroup on siRNA delivery and efficacy.  The best-performing lipid was Dlin-KC2-
DMA, i.e., the LNP on which it was based showed superior efficacy in both rodents and 
non-human primates.  
 
 
28 
 
  
Figure 2.5 Structure of cationic lipids used for siRNA delivery. 
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2.2.1.2 Anionic lipids as carriers for siRNA delivery  
Although most lipid-based delivery systems used cationic lipids as the carrier, 
studies showed that anionic lipids could be used stand-alone or in combination with 
cationic lipids to address specific issues associated with the delivery of siRNA or DNA.  
For example, DNA encapsulated in a cationic-based SNALP formulation can undergo 
deactivation by polyanions present in tumor fluid, such as hyaluronic acid.  The delivery 
issue was resolved by complexing DNA with a polylysine to impart a net positive charge 
on the particle surface, followed by treatment with anionic lipids to increase the 
transfection of DNA to target tumor cell. 
34
 In another study, an LNP constructed with an 
anionic lipid, dilinoleylmethyl-4-dimethylaminobutyrate (DLin-MC3-DMA), showed 
substantially improved siRNA delivery and gene knockdown for the treatment of liver 
disease. 
8
 LNPs constructed with anionic lipids are expected to have an improved safety 
profile relative to LNPs constructed with cationic lipids due to the lack of positive charge.  
For example, cationic lipids have been implicated for non-specific interaction with 
negatively charged cellular components, including opsonins, serum proteins, and 
enzymes. 
35
  This non-specific interaction can interfere with ion-channel activities.  
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Anionic lipids provided a safe alternative to cationic lipids used mostly in SNALP 
formulations.  Development efforts for the anionic lipid-based delivery system have been 
focused primarily on increasing encapsulation efficiency achieved by charge repulsion 
between carrier and siRNA.  A bridging agent is often incorporated to promote the 
association between carrier and siRNA.   
2.2.2  Polymer-based delivery systems  
Polymer-based delivery systems include two major categories, where the 
distinction lies in the nature of the linkage between the polymer carrier and siRNA.  The 
first type is the nanoparticle-based system, where the polymer and siRNA form nano-
aggregates through electrostatic interaction and other non-covalent bonds, while the 
second type is an integrated system, where the polymer, siRNA, and various other 
functional moieties are brought together through reversible covalent bonds.   
2.2.2.1 Nanoparticle-based polymer delivery systems 36, 37,38 
The nanoparticle-based polymer delivery platform utilizes cationic polymers as 
carriers to form a complex with negatively charged siRNA through electrostatic 
interaction.  The complexation process effectively contracts the siRNA to prevent its 
hydrolytic degradation and to facilitate cell-uptake through endocytosis.  In addition to 
polymers, these delivery systems often contain other components to minimize off-target 
effects and to improve cell-targeting efficiency.  The safe and effective delivery via 
polymer-siRNA nanoparticles relies on the particle size, its physical stability during 
extracellular circulation, cellular uptake via endocytosis and efficient release of siRNA 
from the complex through polymer biodegradation.  The polymer includes naturally 
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occurring polycations (e.g., atelocollagen and chitosan) that are biocompatible and 
biodegradable as well as the synthetic ones (e.g., polyethylenimine).  
2.2.2.1.1 Natural polymers as carriers for siRNA delivery 
Natural polymers were among the early candidates explored for siRNA delivery 
owing to their biocompatible and biodegradable nature.  Chitosan is one of the most 
studied natural polymers for cellular delivery.  It is a copolymer consisting of GLcNAc 
(N-acetyl-D-glucosamine) and GLcN (D-glucosamine) building blocks (Figure 2.6).  
The co-polymer carries positive charges under acidic or neutral environment.  The 
decomposition product incurs no toxicity in vivo which makes it a good polymer carrier 
candidate for siRNA.
39
 The thiamine pyrophosphate (TPP) salt of chitosan forms stable 
nanoparticles with siRNA, effectively shielding siRNA from chemical degradation and 
promoting efficient cellular uptake of the siRNA.  The delivery efficiency depends on the 
molecular weight of the polymer and the surface charge of polymer – siRNA complex, 
controlled by the ratio of chitosan-TPP and siRNA.  A polymer with a greater positive 
charge density promotes a stable complex formation. The gene-silencing percentage 
reached a maximum with the lowest particle size of the complex.  The chitosan salt based 
delivery system demonstrated no sign of cytotoxicity based on an MTT (3-(4, 5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay, and the cell viability is ~ 
90% of those untreated cell lines.
40
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Figure 2.6 Chemical structure of natural copolymer chitosan 
 
Atelocollagen is another natural polymer that was explored for gene and/or 
siRNA delivery. 
41
 This natural polymer is prepared by enzymatic digestion of type I 
collagen of calf derma to remove telopeptides, known to cause an immune response.  The 
delivery formulation is typically a simple binary mixture containing polymer and siRNA.  
In vivo gene knockdown achieved with this approach is promising, and the mice that 
received an intravenous injection of natural polymer atelocollagen and siRNA mixture 
showed an 80 to 90% reduction in bone tumor metathesis. 
42
  
2.2.2.1.2 Synthetic polymers as carriers for siRNA delivery 
 
In addition to natural, biodegradable polymers, synthetic polymers were also 
extensively evaluated as potential carriers for siRNA delivery.  The system design 
focuses on rationale selection of the shielding ligands, preventing non-specific interaction 
between nanoparticles and extracellular proteins, and the cell targeting ligands, enabling 
effective cell uptake to the cytoplasm.   
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Figure 2.7 Components of Cyclodextrin (CD)-based nanoparticles for siRNA delivery 44 
 
Cyclodextrin (CD) is a cyclic oligomer with glucose as a building block.  It is a 
pharmaceutical excipient commonly used to enhance solubilization of poorly soluble 
drug in parenteral formulations.  The solubilization enhancement is associated with the 
cavity within the CD that allows host-guest interaction (or complexation).  CD is safe and 
well tolerated for human use and a good candidate for gene delivery. 
43
  A three-
component system (Figure 2.7), consisting of CD-containing linear polymer (CDP), 
PEG- adamantane (AD) and AD-PEG-TF (transferrin), was developed for siRNA 
delivery. 
44
 The CD-containing polymer (carrying polycations) forms nanoparticles with 
siRNA via electrostatic interaction regardless of the size and type of siRNA.  The 
polymer serves as a physical barrier to prevent chemical degradation of siRNA.  The CD 
on the polymer backbone also provides host sites for attaching PEG and PEG-TF 
functional groups with the AD as the anchor.  The PEG group functions as a stability 
enhancer to prevent nanoparticle aggregation, while the AD-PEG-TF structural moiety 
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decorated on the polymer surface enhances the cell uptake, with TF serving as the cell 
targeting ligand.  Finally, the polymer backbone is linked to amine-containing chemical 
groups that were designed to facilitate the release of siRNA from the endosome to the 
cytoplasm.  
Key variables dictating the delivery properties include the type of CD and charged 
groups on the polymer backbone, as well as the distance between the CD and the charged 
groups.  A longer distance between CD and the charge center renders a low toxicity but a 
low binding affinity with siRNA.  Among various positively charged groups (e.g., 
amidine, quaternary amine and secondary amine) evaluated on the polymer backbone, 
amidine stands out as the best.  The formulation preparation is simple and involves 
mixing a naked siRNA from one vial with a pre-mixed CD-containing polymer, AD-PEG, 
and AD-PEG-TF constituents into buffer solution before use.  The final mixture yields a 
stable nanoparticle with a diameter of ~ 70 nm.  The CD-based delivery platform with 
siRNA designed for RRM2 (ribonucleoside-diphosphate reductase subunit M2) gene 
knockdown showed significant suppression of the RRM2 protein.  It was safe and well 
tolerated based on non-human primate and mice models.  The formulation is currently 
being evaluated for safety in an early human clinical trial for treating cancer. 
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Polyethylenimine (PEI) is another popular synthetic polymer often used for DNA 
or siRNA delivery. 
45
 It has a high density of positive charges on the polymer backbone 
under physiologic pH due to the protonated amino groups.  The positive charges in PEI 
enable the formation of stable non-covalent complexes with the negatively-charged 
siRNA.  A linear PEI with MW of 22 kDa achieved the efficient delivery of siRNA with 
minimal cytotoxicity.   Further studies indicated that the delivery efficiency of the PEI 
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system depends highly on the molecular weight and configuration (linear or branched) of 
the polymer and the mass ratio between PEI and siRNA.
46
 The chemical modification of 
PEI with PEG groups improves the transfection efficiency of siRNA while reducing the 
potential toxicity.  The underlying mechanism is that the non-ionic PEG group can reduce 
the potential non-specific interaction between the positive polyplex and extracellular 
matrix, including proteins.  In addition, the amino groups on PEI are implicated in the so-
called "proton sponge effect", 
47
 where they serve as a low pH buffer system in the 
endocytosis/liposomal system, increasing the osmotic pressure and eventually leading to 
the breakage of the endosome membrane to release the siRNA to the cytoplasm.  PEI is a 
non-biodegradable polymer, so the safety profile is less ideal due to the accumulation of 
large MW polymer in cells.      
Bioreducible polymers, such as poly (disulfide amine), were recently reported as 
an effective carrier to deliver siRNA. 
48
  These polymers were prepared through 
copolymerization of low molecular weight cationic monomers containing disulfide 
groups as a reducible linkage.  Compared to non-degradable polymers, such as PEI, the 
bioreducible-based polymer delivery platform would be more biocompatible, intrinsically 
safe and less toxic.  An arginine-conjugated poly(cystaminebisacrylamide-
diaminohexane)  (i.e., poly (CBA-DAH-R)) was developed for VEGF gene-silencing 
siRNA delivery.  The polymer forms 200-nm particles after complexing with siRNA; 
maximal physical stability of the nanoparticles is achieved at mass ratios from 20 to 1 
between polymer and siRNA.  The reducible property of the polymer carrier was 
confirmed by the absence of nanoparticles in a solution of dithiothreitol (or DTT)), where 
DTT mimics a reductive environment.  The degradation of the polymer by DTT disrupted 
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the polymer-siRNA complex.   An in vitro cytotoxicity assay suggested that the system 
with poly (disulfide amine) carrier exhibits ~ 100% cell viability while the PEI polymer 
results in only 40% relative cell viability.   In vitro transfection efficiency is ~ 80% in 
human prostate carcinoma PC-3 cell line, and the high cell uptake indeed correlated with 
significantly suppressed gene expression.  The high gene knockdown efficiency 
associated with poly(disulfide) is attributed to the ability of the disulfide bond in the 
polymer backbone that can be reduced easily.  The importance of reductive cleavage of 
the disulfide bond was confirmed with confocal fluorescence microscopy; the cell lines 
treated with buthionine sulfoximine (BSO), a reagent that can increase the intracellular 
reducing potential, showed a marked decrease in the localization of siRNA in the 
cytoplasm.    
For a nanoparticle-based siRNA delivery system, the polymer choice is typically 
constrained to polycations, where the backbone contains positively charged amine groups.  
With technology advancement in polymer engineering, it is possible to chemically 
modify neutral polymers for potential use as siRNA delivery vehicle.  Poly(ethylene 
oxide) (PEO) and polyester (PE) have been extensively used as vehicles for oral drug 
delivery, thus, their safety and toxicity are well characterized.  The copolymers of PEO 
and PE, grafted with a short cationic moiety, were recently developed as safe and 
effective siRNA carriers with promising in vitro results.  The systems demonstrated 
efficient cell uptake as well as in vitro gene knockdown encoded for P-glycoprotein. 
49
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2.2.2.2  Covalent bond based delivery system: dynamic polyconjugate50 
 
A polyconjugate is a complex formed between a synthetic polymer and a 
biological molecule, such as siRNA.  In contrast to the polymer-based nanocarrier 
delivery systems, where the positively charged polymers form complexes with siRNA 
through electrostatic interactions, the dynamic polymer conjugates chemically link all 
functional groups together through reversible covalent bonding.  The key to the 
polyconjugate delivery system is to maintain the integrity of the chemical bonds before 
delivering siRNA to the target cells.  However, once inside the cell the covalent bonds 
need to self-dissociate to release siRNA to the cytoplasm.   
2.2.2.2.1  Polyvinylether-based polyconjugate  
 
The first polyconjugate achieving such a task was reported by Rozema and co-
workers. 
51
  The negatively charged, non-aggregating siRNA polyconjugate comprised 
reversible linkages attaching three main structural motifs onto the polymer backbone -   
poly(butyl amino vinyl ether) (PBAVE).  The key functional moieties include siRNA, 
PEG (the shielding group) and N-acetylglucosamine (NAG, the cell-targeting group).  
The disulfide bond links siRNA to the polymer backbone, and the PEG and NAG groups 
are attached to the polymer through reversible modification with maleic anhydride 
derivatives.  Polyconjugate enters the hepatocytes through ASGPr-mediated endocytosis.  
The low pH environment of the endosome cleaves the acid-labile maleate bond, releasing 
the PEG and NAG groups.   The de-protected free amine groups can disrupt the 
endosome membrane, releasing the polymer-siRNA conjugate into the cytoplasm.  The 
disulfide bond linking siRNA and the polymer will be subsequently oxidized in the 
cytoplasm, resulting in the release of the free siRNA in the cell. (Figure 2.8 )  
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Figure 2.8 Cell uptake of siRNA-polymer conjugate 51 
 
Both PEG and NAG groups are important for effective siRNA delivery.  The 
dissociation of the PEG group from the polyconjugate in the endosome is the critical step 
for an effective gene knockdown.  When a PEG group was permanently linked to the 
polymer backbone, the polyconjugate was found to become completely inactive.  The 
NAG functional group is also critical to siRNA cell uptake. The hepatocyte uptake of 
siRNA was significantly reduced when NAG was replaced with glucose in the 
polyconjugate assembly, confirming NAG as cell targeting ligand for the liver.  The non-
covalent bonded polyconjugate, where siRNA and polymer were assembled through 
electrostatic interactions, showed a marked decrease in siRNA accumulation in the liver, 
underscoring the importance of covalent bonding between siRNA and polymer backbone.  
Dynamic polyconjugates delivered siRNA effectively to liver cells for both in-vitro and 
in-vivo models.  Significant gene knockdown was demonstrated for apoB and PARP 
genes with maximum efficiency of 80 to 90% at 2.5 mg/kg dose.  The time duration of 
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gene knockdowns is satisfactory.  The dose level tested is well tolerated, and no toxicity 
was indicated based on several safety biomarkers.  The apoB gene silencing with siRNA 
polyconjugates effectively elicits a reduction in apoB gene expression and cholesterol 
level in serum as well as an impairment of triglyceride transport from the liver.  However, 
the fatty liver induced by the gene knockdown and its potential acute effect in humans 
should be further investigated prior to advancing apoB siRNA as a viable therapeutic 
agent.   
The siRNA polyconjugates offer a promising delivery platform for gene-based 
therapeutic applications with high potency and low toxicity.  The reversible covalent 
bonds used in linking siRNA, cell targeting ligand, and shielding ligand provide added 
flexibility for targeting variety cell types.  The key advantage over the nanoparticle-based 
delivery platforms includes minimal accumulation in off-target cells.  The smaller 
particle size of the polyconjugate (~ 10 nm), compared to the nanoparticle delivery 
system (~100 nm), eliminates the potential activation of immune cells, resulting in near 
elimination of toxicity effects.  
2.2.2.2.2  PolyLycine-based polyconjugate 52 
 
A polymer conjugate containing a polylysine (PLL) backbone bonded with PEG 
and 2,3-dimethylmaleicanhydride (DMMan)-masked-melittin (Mel) was recently 
reported as a potential delivery platform for siRNA therapeutic.  The integrated siRNA-
containing polyconjugate was constructed by means of a three-step synthesis.  The first 
step involves the coupling reaction between PEG and the PLL polymer backbone.  Then 
a pH-labile DMMan-masked melittin group is attached to the modified PLL through a 
disulfide bond.  Lastly, the siRNA was incorporated into the delivery cargo (e.g., PEG-
39 
 
PLL-DMMan-Mel) through a reducible covalent bond.  Similar to the PBAVE-based 
system, the PEG group functioned as the shielding agent, and the methylmaleic 
anhydride-masked melittin is the endosomolytic agent, facilitating the escape of siRNA 
under weakly acidic endosomal environment.  The polyconjugate system forms 
nanoparticles with sizes ranging from 80 to 300 nm, significantly larger than the PBAVE 
system discussed previously.  The in vitro gene-silence efficiency was evaluated in 
cultured Neuro2A cells having stable luciferase expression.  The gene-knockdown is ~ 80% 
at low doses (0.125 μg to 0.25 μg).   Despite promising in vitro efficacy, the in vivo 
toxicity studies suggested unusually high toxicity based on a rat model.  Further 
optimization of this delivery platform is needed for therapeutic applications. 
 
2.2.3   Summary of siRNA delivery platforms  
Among the various systems discussed above, siRNA-containing lipid nanoparticle 
(LNP) remains the most advanced delivery platform being tested in human clinical trials. 
The development of LNP systems requires the characterization of several critically 
important quality attributes, among which is the chemical stability of key constituents in 
the LNPs.  The remaining part of the introductory chapter will highlight the challenges 
and opportunities associated with analytical method development for quantitating the 
siRNA, lipids and their related species.  Separation techniques, such as HPLC and CE, 
coupled with various types of detectors—UV, MS, ELSD, and CAD, will be discussed 
with respect to their potential utility in addressing the analytical challenges.   
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2.3        Overview of analytical separation and stability characterization of LNP  
2.3.1   Chemical degradation of RNA and lipids in LNP 
 
             A fully assembled LNP typically contains siRNA, cationic lipids, PEG-
containing short-chain lipids, and cholesterol.  Chemical stability of the LNP is a key 
consideration during formulation development.  Evaluation of the stability performance 
of an LNP system entails the quantitation of active components, including siRNA and 
lipids, and their respective breakdown products due to degradation.  Quantitation of each 
component in LNP is important for verifying a target potency of siRNA and the desired 
lipid composition for achievement of optimum physical properties, such as particle size, 
surface charge, etc.  The analysis and control of low-level breakdown products from 
siRNA and lipids ensures that patients are not exposed to potentially harmful species.  
This analysis and control is also a mandate from regulatory agencies before a new 
therapeutic can be tested in clinical trials.     
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Scheme 2.1 Base-catalyzed intramolecular hydrolysis of the phosphodiester bond in 
RNA. (B denotes a Bronsted base.) 
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Both siRNA and lipids in LNP have the potential to form low-level degradation 
products due to hydrolysis and/or oxidation.  RNA is a complex molecular assembly, 
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consisting of a long chain of nucleotides.  Each nucleotide contains a nitrogenous base, a 
ribose sugar, and a phosphate. The sugar-phosphate backbone of a native RNA molecule 
is subject to hydrolytic degradation.  The hydrolysis is accelerated by both acid and base. 
53
 Scheme 2.1 shows a base-catalyzed intramolecular hydrolysis of the phosphodiester 
bond in RNA.  The bond cleavage proceeds with the displacement of a 5'-linked 
nucleoside by a nucleophilic 2’-oxyanion group (e.g., the deprotonated 2’-OH), forming 
2',3'-cyclic phosphate, which can rapidly hydrolyze to generate the end products.  In an 
acidic environment, the 2',3'-cyclic phosphate intermediate can undergo pseudorotation 
forming an isomer of the starting RNA, in addition to the 3'-5' phosphodiester bond 
breakage. 
54
    
Synthetic siRNA must be chemically modified to improve in vivo serum 
stability
55
; for this, the phosphodiester linkage is modified by phosphorothioate 
substitution.  In addition, the replacement of a hydroxyl group at the 2' position with  
- OMe or -F also stabilizes the RNA (Figure 2.9).  Despite the chemical modification, the 
hydrolytic degradation of a fully modified siRNA can still occur in an actual LNP system.  
In addition to hydrolysis, the phosphorothioate group (Scheme 2.2) and the nitrogenous 
bases in siRNA can undergo oxidation (Scheme 2.3). 
56
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Figure 2.9 Chemical modification of RNA to improve chemical stability 
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Scheme 2.2 Oxidation of phosphorothioate RNA to phosphodiester RNA
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Scheme 2.3 Oxidation of nitrogenous base – Guanine 53 
 
 
 
The chemical stability of lipids varies significantly, depending on their structure.  
Like siRNA, the lipids are prone to hydrolysis or oxidation.  Free radical-mediated auto-
oxidation is typical for lipids with unsaturated alkyl chains.
57
  Scheme 2.4 shows an 
example of autoxidation of a lipid with two double bonds.  The reactive peroxide 
intermediate can further engage secondary degradation, forming complex final products, 
including unsaturated aldehydes, di- and epoxy-aldehydes, lactones, furans, ketones, and 
oxo and hydroxyl acids, etc.  Lipids containing ester groups (e.g., dipalmitoyl- 
phosphatidylcholine (DPPC)) are prone to hydrolysis, resulting in the formation of fatty 
acids and the lyso form of the parent lipid (Scheme 2.5). 
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Scheme 2.4 Autoxidation of unsaturated lipids 
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Scheme 2.5 Hydrolysis of dipalmitoylphosphatidylcholine (DPPC). 
 
 
 
2.3.2 Overview of separation techniques for oligonucleotides  
 
Many separation techniques have been explored in the past for the analysis of 
oligonucleotides.  These include polyacrylamide gel electrophoresis (PAGE), capillary 
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gel electrophoresis (CGE), anion-exchange chromatography, and ion-pair reversed-phase 
liquid chromatography (IP-RPLC).  The techniques developed for oligonucleotides, in 
theory, are applicable for the analysis of siRNA and their potential degradation products 
in LNPs.  The separation method should afford sufficient selectivity between siRNA and 
its potential hydrolytic breakdown products, which often differ by one or two nucleotides 
from the parent molecule.  Furthermore, the method should enable the separation of 
siRNA with a phosphorothioate linkage from its potential oxidation product (i.e., siRNA 
with a phosphodiester linkage).  High performance liquid chromatography (HPLC) is an 
ideal technique to fulfill this need.  With the introduction of sub- 2μm particles in column 
with a narrower outer diameter, coupled with significant improvement in instrument 
hardware, HPLC has superior separation efficiency, excellent accuracy, and precision.    
The technique encompasses a broad range of separation modes including normal phase, 
reverse phase, ion-exchange, ion-pair chromatography, etc.  Due to the extreme polarity 
of oligonucleotides (RNA or DNA), an early study suggested that separation using 
conventional reversed-phase HPLC would be challenging. 
58
 Anion exchange 
chromatography has the potential to provide adequate resolution for RNA analysis due to 
charge interaction between RNA with negative charges and anionic exchangers on the 
stationary phase. 
59, 60,61  
 IP-RPLC also provides adequate separation for oligonucleotides 
due to a retention mechanism that is similar to ion exchange chromatography.  
62,63,64 
  
Capillary electrophoresis (CE) is another attractive technique for siRNA analysis, 
largely due to its ultra-high separation efficiency, fast analysis time and its charge-to-
frictional-drag-ratio based separation mechanism that is compatible with negatively 
charged siRNA analytes.  Since the differences in charge-to-frictional-drag ratios for 
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different RNA molecules diminish rapidly as the number of nucleotides exceeds 10, the 
separation of a typical sample of siRNA (21 to 23 mers) would require capillary gel 
electrophoresis (CGE), where the polymer network in the gel provides separation for 
large oligonucleotides.  The differential migration in CGE is based on both charge and 
molecular size.
65
   
The detection of siRNA is relatively straightforward since one of the building 
blocks of siRNA, the nucleoside, exhibits a large molar absorptivity in the UV region, 
making the diode array absorbance detector an excellent choice for detection.  Further 
structural elucidation of potential degradation products would require the use of in-line 
mass spectrometry following the LC separation.  Liquid chromatography electrospray 
ionization mass spectrometry (LC-ESI-MS) is a standard technique in the pharmaceutical 
industry for quantifying the active drug and its metabolite(s) in biological fluids.  Its 
application to oligonucleotides is promising but not without challenges, such as the (i) 
limited ionization efficiency and signal suppression due to significant adduct formation 
with sodium or potassium cations; and (ii) potential inconsistency of chromatographic 
resolution and mass detection in terms of mobile phase selection.
66
   
2.3.2.1 Ion-pair reversed-phase liquid chromatography  
 
Ion-pair reversed-phase liquid chromatography (IP-RPLC) is an extension of 
traditional RPLC.  Both techniques share some common features, including the 
hydrophobic organic mobile phases and nonpolar stationary phases that are employed.  
The key difference between them is the inclusion of small organic salts (e.g., sodium 
hexane sulfonate or tetrabutylammonium acetate) in the mobile phase for IP-RPLC.  The 
hydrophobic portion of ion-pair reagent adsorbs onto the C18 phase of the column, 
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providing a dynamic ion-exchange phase for the retention of analytes with opposite 
charges.  The overall retention in IP-RPLC is related to charge and hydrophobicity of the 
analyte.  The separation selectivity can be tuned by varying the identity and/or 
concentration of the ion-pair agent, the pH of the mobile phase, and the identity and/or 
percentage of organic solvent in the mobile phase.  Like regular RPLC, the stationary 
phase can significantly impact the selectivity in IP-RPLC.   
The separation mechanism of oligonucleotides in IP-RPLC was systematically 
studied by comparing the retention time of an array of homo-oligonucleotides (< 40 mers) 
and various oligonucleotides with a minor structural difference on two types of stationary 
phases, the Clarity Oligo-RP and Synergi Polar RP.   In addition to the hydrophobic 
interactions, the studies suggested that dipolar and π- π interactions also contributed 
significantly to retention.  Columns that can provide these additional interactions 
provided a better resolution between oligonucleotides that differ by one base pair or by 
one nucleotide unit. 
67
   
An IP-RPLC method was developed to quantify and characterize the antisense 
oligonucleotides, their impurities, and major metabolites. 
64 
The separation was 
performed on a capillary HPLC system with a Terra MS C18 column packed with 2.5-µm 
porous sorbent.  The small particle size improves the separation efficiency by reducing 
band broadening due to eddying or resistance to mass transfer.  Figure 2.10 compares a 
typical chromatogram of a mixture of 7- to 30-mer oligonucleotides on RP-HPLC with a 
typical chromatogram of the same mixture on CGE.  The separation is highly dependent 
upon the selection of ion-pair reagent.  Figure 2.11 compares the separation of 25-mer 
phosphorothioate oligonucleotide by means of the triethylammonium acetate (TEAA) 
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ion-pair system with that by means of triethylamine-hexafluoroisopropanol (TEA-HFIP).  
The former system showed no resolution of individual oligomers, while the latter system 
demonstrates baseline resolution.  An increase in TEA concentration further improves the 
separation. The superior resolution achieved with TEA-HFIP is attributed to a reduction 
of the impact of the oligonucleotide’s hydrophobicity on retention, a reduction that 
appears to be crucial to a successful separation.  The mobile phase composition not only 
impacts the separation, but it also significantly influences the mass spectrometry signal 
used as one means of the detection.  TEAA at 100 mM concentration significantly 
suppresses the ionization efficiency of the oligonucleotides.  The best signal-to-noise 
ratio for MS was achieved with TEA-HFIP.  
 
 
 
Figure 2.10 Separation of 30-mer homooligodeoxythymidines on A: ion-pair reversed- 
phase LC; and B: capillary gel electrophoresis. 
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Figure 2.11 Impact of ion-pair reagent on the separation of phosporothioate 
oligonucleotides (19- to 25-mer); A: TEAA; B: TEA-HFIP 
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The ion-pair RPLC was also employed for the analysis and purification of siRNA.  
The oligonucleotides were separated using an X-Bridge C18 column.  The mobile phase 
components consisted of aqueous 0.1 M TEAA (pH 7) and 80/20 aqueous 0.1 M 
TEAA/ACN.  A gradient elution method was developed to separate the target siRNA 
duplex from its synthetic impurities - potential mismatched duplexes arising from the 
annealing of a mixture of a full-length upper strand and its complementary truncated 
lower strand. 
68
   
2.3.2.2 Ion-exchange chromatography  
 
Ion-exchange chromatography (IEC) has some similarity to IP-RPLC in terms of 
the retention mechanism.  Their key difference lies in the nature of the association 
between ion exchangers and column stationary phase support.  For IEC the ion 
exchangers are covalently bonded to the column stationary phase.  Quaternary 
ammonium and sulfonate groups are characterized as strong ion exchangers.  The 
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selectivity in IEC can be optimized through changes in pH, salt or buffer type, stationary 
phase, and mobile phase composition.  
 
 
 
Figure 2.12 Anion exchange chromatograms of (a) a mixture containing full-length, fully 
thioated, 20-base oligonucleotide, 5'-GCC CAA GCT GGC ATC CGT CA-3', and its 
mono-, di-, and triphosphodiester analogs and (b) 1:1 solution of full-length 5%-GCC 
CAA GCT GGC ATC CGT CA-3% sequence and a mixture of its (n-1) deletion 
sequences. 
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Anion exchange chromatography demonstrated an effective separation for 
oligonucleotides (20 bp) with fully thioated phosphorothioate linkages and its structural 
analogs with mono-, di-, or tri-phosphodiester substitution (Figure 2.12).  The separation 
was performed on a GEN-PAK FAX or a HEMA IEC BIO column, which contains 
diethylaminoethyl cellulose or hydroxyethyl methylamine as the stationary phase. 
Gradient elution was employed, with the mobile phase containing pH 8 Tris buffer as 
solvent A and IPA or MeOH as solvent B.  However, the method was not able to 
differentiate full-length oligonucleotides from their n - 1 single deletion impurities.  
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Complementary to ion exchange chromatography, CGE provides excellent selectivity for 
an oligonucleotide and its n - 1 single deletion, but it fails to achieve adequate separation 
for oligonucleotides with the same length and sequence but with minor differences in the 
number of diester groups. 
69
  Later, Yang and coworkers reported a strong anion 
exchange chromatography method (Mono Q column) for separating structural analogs of 
14-mer oligonucleotides.
70
  The stationary phase is composed of a quaternary amine 
bound to polystyrene-divinyl benzene beads, exhibiting a strong interaction with the 
negatively charged oligonucleotides.  An acceptable resolution was achieved for 
oligonucleotides with phosphodiester groups as compared with those having single 
substitution with monothiophosphate (PS) and dithiophosphate (PS2).  In this study, the 
type of counter ions (Cl
- 
vs SCN
-
) and their concentration had a significant impact on the 
selectivity.  The results also suggested that retention is linearly related to the number of 
sulfur groups in the oligonucleotide.  
The key challenge with anion exchange chromatography is to improve the 
resolution of oligonucleotides that differ only by one nucleotide, which could be the case 
for siRNAs that undergo hydrolytic degradation (causing single deletion).  New 
stationary phase chemistry has the potential to improve the resolution of ion exchange 
chromatography.  In a recent study, a monolithic capillary column incorporating poly 
(N,N,N-triethylammonium-2-hydroxypropyl-methacrylate-co-divinylbenzene) as the 
stationary phase was prepared for separation of oligonucleotides.  The column provided 
the baseline separation of oligonucleotides with 12 to 18 base pairs. 
71
 (Figure 2.13)  
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Figure 2.13 Effect of mobile pH on the separation of d(pT)12 -18 using N,N,N-
triethylammonium-2-hydroxypropyl-methacrylate-co-divinylbenzene as stationary phase. 
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2.3.2.3 Capillary electrophoresis 
 
Capillary electrophoresis is a separation technique where the analytes are 
separated based on a difference in electrophoretic migration velocity (e.g., capillary zone 
electrophoresis).  The electrophoretic migration velocity is linearly proportional to the 
electrophoretic mobility, which in turn is related to charge and size of the analyte.  The 
migration velocity of the analyte in a capillary also depends on the rate of electroosmotic 
flow (EOF).  When an electric field is applied across the capillary filled with slightly 
acidic to strongly basic buffers, negative charges are formed in the inner surface of the 
silica capillary as result of deprotonation of silanol groups.  Hydrated cations in a buffer 
solution associate with negatively charged silanol groups, creating an electrical double 
layer.  When an electric voltage is applied across the capillary, the positive ions in the 
diffuse region of the electric double layer will migrate toward the anode, pulling water 
along and creating a bulk electroosmotic flow.  The velocity of the liquid in a narrow 
tube is nearly uniform across the inner diameter of the capillary resulting in a plug flow, 
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which is in direct contrast to the parabolic flow exhibited in the pumped flow of a packed 
HPLC column.   
Many separation modes have been developed in past decades using CE for 
various applications.  Those include capillary zone electrophoresis (CZE), capillary 
isoelectric focusing, and capillary gel electrophoresis (CGE).  CGE is mostly used for 
bimolecular analysis due to the added retention mechanism related to the size and 
conformational feature of the analytes.  CGE is a slight variation from CZE, where the 
separation is performed in a polymer matrix filled with buffer.  The porous network of 
the polymer gel will hinder the migration of the analytes to different extents depending 
on their frictional drag (related to molecular size), which has proven to be useful for 
DNA and RNA analysis.      
As mentioned previously, CGE is not suitable for separating oligonucleotides 
with minor structural differences in the ribose-phosphate linkage (phosphorothioate vs 
phosphodiester), but it does provide superior resolution for oligonucleotides that differ by 
only one nucleotide.  The first comprehensive study on RNA separation by means of 
CGE was reported by Skeidsvoll and Ueland in 1996.  The results suggested that the type 
of gel polymer, gel concentration, electrical field strength, and temperature are the key 
variables impacting the separation of RNA with a different number of base pairs.  RNAs 
with base pairs ranging from 100 to 6000 were well separated under an electric field of 
200 V/cm in a separation medium consisting of tris-borate, urea and 0.3% HPMC. 
72
  In 
another example, baseline resolution was achieved for a mixture of six phosphorothioate 
oligonucleotides (16 to 21 mers) differing in length by one nucleotide (Figure 2.14). 
73
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The separation was performed with a gel matrix and elution buffer consisting of 10% 
micro-gel in the tris-borate buffer at pH 9.    
Most CGE methods were developed for analyzing single-stranded 
oligonucleotides.  For duplex RNA or DNA, the samples are typically denatured first 
(into separate strands) prior to analysis.  However, the direct analysis of double-stranded 
oligonucleotides has occasionally been attempted.  The results suggested that duplex 
nucleotides tend to denature on the column, resulting in the formation of two 
complementary single strands during the separation.  Further study suggested that low-
level metal ions (e.g., Na
+
 or Mg
2+
) in the separation buffer can stabilize the duplex and 
suppress the on-column formation of single-stranded oligonucleotides.  However, the 
resolution of duplex oligonucleotides from their analogs with n - 1 nucleotide is much 
poorer than that of single-stranded oligonucleotides.
74
    
 
 
 
Figure 2.14 Electropherogram of a mixture of six phosphorothioate oligonucleotides (16-
21 mers) differing in length by one nucleotide. (Electrophoresis was conducted with an 
electrokinetic injection at -8 kV for 5 s, and a constant running voltage of -22 kV was 
used.) 
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2.3.3 Overview of lipid separation and analysis 
 
Lipids are in a class of biomolecules covering a wide range of chemical structures.  
The structural diversity is essential to their biological functions.  Aside from composing 
the membrane bilayer, lipids also provide an energy source for metabolism and 
participate in metabolic processes, including signal transduction, secretion, and protein 
trafficking. 
75,76
 The comprehensive analysis of lipid species, their related networks, as 
well as their metabolic pathways at the molecular level, has evolved into an exciting 
research field – known as lipidomics – more than 14 years ago. 77,78 Separation 
techniques, coupled with powerful structure characterization tools, such as mass 
spectrometry or NMR, are at the forefront in addressing fundamental questions around 
the biological roles of lipids in human health and disease.
79, 80, 81
  
Prior to the development of HPLC techniques, lipids were analyzed by means of 
GC, but thermal degradation concerns during the sample introduction process limit this 
approach for broad applications. 
82
 Although there are some reports on the use of 
capillary electrophoresis for lipid analysis, 
83
  its predominant use of aqueous separation 
media prevents its application to the analysis of non-polar lipids, which have solubility 
issues in aqueous media.  As a product of the earlier efforts towards the development of 
liquid chromatography, thin-layer chromatography (TLC) has been used quite 
extensively for lipid analysis because of its simplicity and high-throughput.  The refined 
version of high-performance TLC is a valuable tool for the analysis of different classes 
of lipids.  Among all the separation techniques, HPLC is often the method of choice for 
total lipid analysis.  Two common separation modes are normal phase HPLC and 
reversed phase HPLC. 
84,85
 Normal phase HPLC separates lipids based on an 
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adsorption/desorption process, where the interaction between hydrophilic moiety in the 
lipid (e.g., the polar head-group) and the polar stationary phase dominates the retention 
mechanism.  The separation of the lipids in NP-HPLC is more selective for structural 
differences between lipid classes than within a lipid class.  Figure 2.15 shows the 
separation of representative lipid classes by means of normal phase chromatography. 
86
 
 
 
Figure 2.15  Separation of lipid classes representatives (1) PAR (paraffin, liquid), (2) 
WE (n-hexyldecyl palmitate), (3) CE (cholesteryl palmitate), (4) FAME (stearic acid 
methyl ester), (5) TAG (glycerol tripalmitate), (6) FOH (hexadecyl alcohol), (7) FFA 
(stearic acid), (8) CHOL (cholesterol), (9) 1,3-DAG (glycerol-1,3-dipalmitate), (10) 1,2-
DAG (glycerol-1,2-dipalmitate), (11) MAG (glycerol monopalmitate) and (12) FAA 
(erucylamide) 
86 
 
 
For reversed-phase HPLC, the lipids are separated based on overall polarity, the 
degree of saturation in the alkyl chain, and the chain length, thus providing a greater 
selectivity for lipids of different structure within classes than the normal phase separation 
mode provides.  Both isocratic and gradient mobile phase conditions with reversed-phase 
HPLC were reported for the separation and analysis of lipids in relatively simple sample 
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matrices.  For example, an isocratic HPLC method was developed for the analysis of 
cholesterol, 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), and degradation products 
of DOPC, including oleic acid and lysophosphatidylcholine. 
87
 The separation was 
accomplished in 20 minutes with satisfactory resolution on a Basil BDS C8 column.  The 
mobile phase was comprised of pH 2.7 phosphate buffer and MeOH at a 15:85 volume 
ratio.  The validation was excellent with respect to specificity, linearity, and recovery and 
precision.  Zhong et al. reported the analysis of cationic liposomes with RPLC coupled to 
an evaporative light scattering detector (ELSD).  A gradient method was developed that 
provided an excellent separation of 1,2-dioleoyl-3-trimethylammonium propane 
(DOTAP), 1,2-distearoyl-sn-glycero-3-phosphatidylcholine (DSPC), DPPC, and 
cholesterol within 15 minutes (Figure 2.16).  The method was also capable of separating 
lipid degradation products, including the fatty acids and the lyso forms of lipids (i.e., the 
remaining part of the lipid after the loss of an acyl group from the sn - 1 position of the 
parent lipid).  Since DPPC and DSPC have very weak UV absorption, the principal 
means of detection was an ELSD.  A limit of quantification (LOQ) of 0.3 µg was 
demonstrated with the nebulizer and evaporator temperature of the ELSD set at 50
o
C and 
75 
o
C, respectively.  The N2 gas flow was set at 1.5 ml/min. 
88
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Figure 2.16 Example chromatogram of forced degradation of a lipid mixture using 0.1N 
HCl at room temperature for 4 days. 
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Most of the bonds in lipids are C-C and C-H bonds, resulting in very weak UV 
chromophores and thus poor sensitivity with a UV absorbance detector.  Universal 
detectors, such as the evaporative light scattering detector (ELSD)
 89
  and the charged 
aerosol detector (CAD)
 
,
90
 are often the detector of choice for routine analysis of lipids.  
The key advantage of ELSD is the universal signal response as a function of analyte 
concentration, regardless of the spectral properties.  There are three steps involved in 
ELSD operation, the nebulization of the eluent from the mobile phase, the evaporation of 
residual solvent and quantitation of non-volatile dried particles based on light scattering 
technique.  The signal response is highly dependent upon the distribution and average 
value of the droplet size in the nebulization, which in turn depends on (i) the flow rate of 
the mobile phase, (ii) the nebulization gas, and (iii) the mobile phase composition.   The 
key limitation of the ELSD is its relatively high limit of quantitation (LOQ, ~ 0.1 µg) and 
narrow dynamic range (2-3 orders of magnitude).  Also, this detector has little tolerance 
to buffer salt, and the mobile phase has to be volatile.   
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Another alternative to the UV absorbance detector is the charged aerosol detector 
(CAD), which was introduced commercially in 2005.  It has many features in common 
with the ELSD but a markedly improved limit of quantification (low ng to high ug) and a 
wider dynamic range (four orders of magnitude).  A minor drawback for both ELSD and 
CAD is the slightly non-linear relationship between the analytical signal and analyte 
concentration.  The operational principles for CAD are similar to ELSD in the 
nebulization and evaporation steps.  The key distinction lies in the last step where the 
CAD transfers charge to the dried sample particles with N2 gas that has passed a high-
voltage platinum wire.  The resulting charged particles are then measured by an 
electrometer.  The CAD also demonstrates better reproducibility than ELSD.   
 
 
2.4     Research objectives and rationales  
 
Lipid nanoparticle (LNP) has emerged as a promising delivery vehicle for siRNA 
therapeutics that can potentially overcome the barriers to drug delivery.  The 
development of a safe and efficacious LNP formulation is labor-intensive.  The process 
involves the characterization of several critically important quality attributes, among 
which is the chemical stability of key constituents in the LNP systems.  This research 
focused on three objectives aiming to address the challenges associated with stability 
characterization of the LNP systems.  The first objective was to develop a separation 
method that can monitor the stereoisomers of a chemically modified siRNA and their 
potential oxidation products.  Various chemical modifications are often made to synthetic 
RNA to prevent hydrolysis by endonucleases.  The phosphorothioate modification is 
commonly used to improve siRNA stability.  The phosphorothioate linkages introduce 
60 
 
additional chiral centers to siRNA, forming multiple stereoisomers that have different 
biological activities.  A separation method capable of resolving siRNA stereoisomers can 
be a valuable tool to study the structure and gene-silencing activity relationship of the 
stereoisomers.  Furthermore, the method can be used to characterize the chemical 
stability of the siRNA stereoisomers.  The siRNA with phosphorothioate modification 
can undergo desulfurization in the presence of oxidants, where the sulfur atom is replaced 
by an oxygen atom.  Desulfurization reaction is detrimental to siRNA stability due to 
hydrolysis and should be closely monitored and controlled in the formulation.  Separation 
of closely related siRNA stereoisomers is a well-noted challenge in the field of separation 
science.  This research attempted to bridge the gap in the literature by studying key 
chromatographic parameters central to the separation of siRNA stereoisomers by means 
of ion-pair reversed-phase HPLC.   
The second objective of the research was to develop an integrated separation 
methodology that can quantify siRNA, lipids, and their potential degradation products.  
Such enabling separation method can significantly increase the speed and throughput 
during the pre-clinical evaluation of LNPs, where a large array of formulations 
containing multiple siRNAs and lipids are routinely analyzed to support various in vivo 
studies.  To ensure a universal use of the proposed separation method for an LNP system 
where multiple siRNAs and lipids might co-exist, we deliberately selected a series of 
siRNAs with different sequences and chemical modifications as well as a range of lipids 
with different chain lengths and head groups for the study.  While there is a significant 
literature presence concerning the separation of RNA or lipids in their respective sample 
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matrix, to the best of our knowledge, there is no prior work on the simultaneous 
separation of siRNAs, lipids, and their related impurities.   
Lastly, the research aimed to map out the main degradation pathways for a 
chemically modified siRNA by means of forced stress testing.  Forced stress testing is a 
useful tool that can predict a stability problem during formulation development.  Few 
studies have been reported in the literature to use this predictive tool to study the stability 
performance of a chemically modified siRNA.  Here we systematically evaluated the 
stability attributes of a model siRNA under various stress conditions.  The goal was to 
provide a mechanistic understanding of siRNA degradation chemistry and a scientific 
framework for a rational selection of the key functional excipients for the LNP 
formulation.     
Among the various separation techniques reviewed in Chapter 2, we selected ion-
pair reversed-phase liquid chromatography (IP-RPLC) as the method of choice for our 
research.  The selection was based on a careful comparison of the advantages and 
disadvantages of the main techniques for RNA and lipid analysis.  Ion exchange 
chromatography (IEC), IP-RPLC, and capillary gel electrophoresis (CGE) are attractive 
techniques that have been used widely for RNA analysis.  For IEC, the separation is 
based on differential electrostatic affinities of the negatively charged RNAs for the 
positively charged stationary phase.  The main advantage of the technique is its ability to 
separate RNA and its common N-x deletions, where N represents the number of base 
pairs in the parent RNA and x stands the number of the base pairs removed from the 
parent strand.  The technique is also capable of separating RNA with phosphodiester (PS) 
linkages from that with phosphorothioate (PO) linkages, where the structural difference 
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between the samples can be a single atom: sulfur instead of oxygen.  The change of one 
atom on such a large molecule can still create enough difference in charge to allow 
separation by anion exchange chromatography. The disadvantage of IEC is that the 
technique is not very selective for RNAs that are the same length but have different base 
pairs.  In addition, the mobile phase for IEC contains a high concentration of non-volatile 
inorganic salts, which is not compatible with a mass spectrometer and requires an 
additional interface between the LC and the MS detector to remove the salts (i.e., a 
desalting step).   
The separation in CGE is primarily based on the length of the oligonucleotide 
strand.  The electrophoretic mobility of the analyte is also influenced by the type and 
concentration of the polymer gel.  The key advantage for CGE is its extraordinary 
resolving power, which allows the separation of the RNAs based on size and charge.  
Similar to IEC, the technique lacks the selectivity in separating RNAs that have the same 
length but minor difference in base pairs.  The technique can be interfaced with a mass 
spectrometer, but it requires significant efforts to remove the high concentration of non-
volatile salts and buffers that are typically used for the separation.  
IP-RPLC separates RNA based on both electrostatic and hydrophobic interactions 
between the analytes and the stationary phase.  The technique offers many advantages in 
RNA separation that are similar to IEC.  Like IEC, IP-RPLC separates RNA based on the 
length of the strand, providing an excellent selectivity for RNA and its N-x deletion 
products.  IP-RPLC is also capable of separating RNAs with PO and PS linkages, which 
is similar to IEC.  What differentiates IP-RPLC from IEC is its ability to separate RNA 
from its potential impurities that have the same length as the parent strand but with 
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different base pairs.  Furthermore, IP-RPLC can employ volatile ion-pair reagents, and 
thus can be directly interfaced to a mass spectrometer for structural characterization.   
Among the three techniques discussed so far, ion-pair reversed-phase HPLC 
emerged as a lead option for RNA analysis owing to its dual retention mechanism and 
has the potential to separate RNA and its closely related degradation products.   
Furthermore, it is likely the only technique suitable for separating both RNAs and lipids.  
The extremely hydrophobic nature of the lipids makes their separation difficult with IEC 
or CGE; both are mostly aqueous-based separation techniques.   
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Chapter 3: Separation of siRNA stereoisomers using ion-pair reversed phase liquid 
chromatography 
The contents of this chapter were previously published in the following peer-reviewed 
article, with the first author contributing substantially (≈ 80-90%): Li Li, Tony Leone, Joe 
P. Foley, and Christopher J. Welch, J. Chromatogr. A 2017, 1500. 84-88, DOI: 
10.1016/j.chroma.2017.04.008. 
 
3.1 Introduction 
Small interfering RNAs (siRNAs) are complex molecular assemblies consisting 
of a duplex of RNA strands with a chain length of about 21 nucleotides.
1,
 
2
 The sugar-
phosphate backbone of native RNA is subject to enzymatic degradation by nucleases and 
also by non-enzymatic hydrolytic degradation, which can be accelerated by acidic or 
basic conditions.
3
  Synthetic siRNAs often incorporate chemically modified nucleotides 
to improve in vivo serum stability, with replacement of the phosphodiester linkage by a 
phosphorothioate moiety being a common motif.
4
  The modification of the hydroxyl 
group at the 2' ribose position with methoxy (–OMe) or fluorine (F) is also routinely used 
to stabilize the siRNA against hydrolysis.  The phosphorothioate group in synthetic 
siRNAs can undergo oxidation in a desulfurization process that replaces the sulfur atom 
with oxygen.  Studies showed that an antisense RNA drug, ISIS-2302, underwent 
spontaneous phosphorothioate desulfurization in a PEG-based formulation, with the 
oxidation being mediated by residual peroxides present in the excipients. 
5
  
Desulfurization of phosphorothioate linkages has also been reported to take place during 
ESI-MS analysis, where abundant peroxy radicals formed in the gas phase promote the 
replacement of sulfur with oxygen.
6
  Desulfurization of phosphorothioate-containing 
siRNAs has implications for the in vivo and in vitro chemical stability of siRNA 
therapeutics, and it is therefore important to develop selective and sensitive separation 
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methodologies to monitor the desulfurization of the phosphorothioate-containing siRNAs 
to ensure their stability during storage and administration.   
Recent advances in RNA-based therapeutics have focused attention on the 
challenging problem of chromatographic separation of complex mixtures of closely 
related oligonucleotides.  A number of sophisticated separation methods have been 
reported to improve resolution for the accurate quantitation of oligonucleotides in 
complex sample matrixes.  Separation modes for the chromatographic separation of RNA 
oligonucleotides include ion-pair reverse phase HPLC,
7,8,9,10,11
 ion-exchange 
chromatography
12
, mixed-mode reversed-phase with ion-exchange chromatography
13
 and 
HILIC.
14
  Two-dimensional separations combining IP-RPLC or ion exchange LC with 
CE have been developed to further improve the resolution of oligonucleotides in highly 
complex sample matrixes.
15
 Separation of chemically modified siRNAs containing 
phosphorothioate groups presents an additional challenge due to the presence of closely-
related diastereomers.
16
  Diastereomers of small or macromolecules can have unique and 
different structural and physical properties; hence separation with achiral columns is 
often feasible, with efforts primarily focusing on separation mode and selection of 
appropriate stationary and mobile phase combinations.  Although the chromatographic 
separation of some phosphorothioate stereoisomers has been reported for 15 to 30 mer 
single-stranded RNAs using strong ion exchange or reversed phase HPLC,
17,18
 there 
remains a gap in the literature on systematic investigations of the separation of the 
diastereomers of complex siRNA duplexes containing multiple phosphorothioate 
stereocenters.  In this study, an ion-pair reversed-phase HPLC (IP-RP HPLC) method 
was developed to resolve the related diastereomers of an siRNA designed to target the 
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ApoB gene.
19, 20
  We herein report an investigation of the influence of column chemistry, 
organic modifier, gradient conditions and the type and concentration of ion-pair reagent 
on the IP-RP UHPLC separation of these stereoisomers. 
 
3.2 Material and methods  
 
3.2.1 Chemicals 
The siRNA duplex and the complementary single strands targeting ApoB gene 
were provided by Merck Sharp & Dohme (MSD) RNA synthesis group.  Ion-pair 
reagents were sourced from two vendors: ethylamine, diethylamine, triethylammonium 
acetate buffer (pH 7, ~ 1.0 M in water) and tetramethylammonium acetate tetrahydrate, 
99%, propylamine, 99% were purchased from Sigma-Aldrich (St. Louis, MO, USA), 
whereas dipropylammonium acetate (0.5 M in Water) was acquired from Fisher 
Scientific (Norristown, PA 19403, USA).  HPLC grade acetonitrile, methanol, 
tetrahydrofuran as well as the crystalline Iodine (99%) were obtained from Fisher 
Scientific.   
3.2.2 Instrument  
An Agilent 1290 Infinity UHPLC system (Agilent Technologies, Santa Clara, CA, 
USA) was employed for the separation of siRNA stereoisomers.  This UHPLC system 
consisted of a binary pump, a diode array detector, an autosampler and a column heater, 
and could be operated at a pressure up to 1200 bars.  To measure siRNA melting 
temperature, a differential scanning microcalorimeter (MicroCal, LLC, Northampton, 
MA, USA) was used, which can operate over a temperature range of -10° to 130° Celsius.  
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3.2.3 IP-RP Chromatographic conditions 
For the separation of siRNA diastereomers, the samples were subjected to 
gradient elution using sub-2um UHPLC columns.  The columns studied in this work 
included the Acquity BEH C18, BEH phenyl, and Ascentis Cyano, with nominal particle 
sizes of 1.7 or 2.0 m and the same column dimensions (150 x 2.1 mm).  Mobile phase A 
consisted of an ion-pair reagent in water (pH 7) and mobile phase B was a mixture of 
20% A and 80% organic modifier (either ACN, MeOH or THF).   The initial gradient 
method was run from 6% to 14% B in 20 minutes, followed by a steeper gradient elution 
from 14% to 30%B in 7 minutes.  The final optimized gradient program is summarized in 
section 3.4.  The siRNA sample was prepared in 20 mM phosphate buffer (pH 7) at a 
concentration of approximately 0.1 mg/mL.  
To achieve an optimum separation, the column should be equilibrated with a 
minimum of 12 column volumes (e.g., ~ 6 mL) of the mobile phase at initial composition.  
The column cleaning involved flushing the column with a minimal of 20 column volumes 
of 50:50 acetonitrile/water at 40
o
C.  The column is stored in 50:50 ACN/water when not 
in use.  The overall of lifetime of the column was not determined at this point. 
3.2.4 Differential scanning calorimetry method condition  
The melting temperature (Tm, or dissociation temperature) of the siRNA duplex 
was measured with capillary cell micro-calorimetry.  A 2 mg/mL siRNA sample solution 
was prepared in 0.1 M TEAA or 0.1 TEAA containing 10% of organic modifiers, such as 
ACN or MeOH.  The sample solutions were added to a 96-well plate and automatically 
applied to the sample capillary controlled by a run sequence.  A heating and cooling cycle 
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from 5
o
C to 90
 o
C was applied to both the reference and sample cells with a scan rate of 1 
˚C/minute.  Each sample was run in triplicate.  
3.2.5 Desulfurization of siRNA duplex using Iodine 
Iodine solution was used as the oxidizing agent to promote the replacement of 
sulfur by oxygen in phosphorothioate-containing oligonucleotides.  The reaction was 
initiated by adding 500 µL of 0.3 mM iodine solution in ethanol to 4500 µL of the siRNA 
with molar ratio of about 30 to 1, iodine to siRNA.  The siRNA sample solution was 
analyzed by UHPLC for approximately four hours after the iodine was introduced.   
 
3.3 Results and Discussion 
 The ApoB gene targeted by duplex siRNA consists of 21-nucleotide sense strand 
and 23-nucleotide antisense strand (Figure 3.1a).  The sense strand contains one 
phosphorothioate stereocenter, which, together with the stereocenters on the ribose sugar, 
results in one pair of diastereomers, while the antisense strand contains two 
phosphorothioate stereocenters, resulting in two pairs of diastereomers.  Consequently, as 
shown in Figure 3.1b and 3.1c, a total of six single strand RNA stereoisomers are present 
in the denatured siRNA duplex, while eight different stereoisomers (four pairs of 
diastereomers) of the siRNA duplex are possible.  
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Figure 3.1a Structure of the siRNA duplex that targets the ApoB gene studied in this 
investigation.  Nucleotides marked with asterisks contain chemically modified ribose 
substituents in which the 2’-OH is replaced with 2’-methoxy.  In the nucleotides 
highlighted in red, naturally occurring phosphodiester linkages have been replaced with 
phosphorothioate linkages.  
 
 
Figure 3.1b: Six single-stranded siRNA species at high temperatures 
 
77 
 
 
Figure 3.1c: Eight diastereomeric siRNA duplexes at low temperatures 
 
3.3.1 The impact of column stationary phase on the separation of siRNA 
stereoisomers 
 
Acquity BEH and Ascentis fused-core UHPLC columns of different stationary 
phase chemistry, including C18, cyano and phenyl, were explored for the separation of 
the six related stereoisomeric single stranded RNAs shown in Figure 3.1b.  The UHPLC 
separation was performed at two column temperatures, 45
o
C and 80
o
C, where the siRNA 
is partially or completely denatured during gradient elution.  The columns studied in this 
work can tolerate high temperature based on column care and use information provided 
by the vendor.  Figure 3.2a shows the overlaid chromatographic traces for the analysis of 
the siRNA duplex on various UHPLC columns at 45
o
C.  The results suggest that all three 
types of columns can resolve up to five species, albeit with relatively poor peak shape.  
The poor separation at 45
o
C is not totally unexpected since there are eight diastereomers 
of the siRNA duplex, making baseline separation very challenging.  Figure 3.2b shows 
the separation of the siRNA mixture at 80
o
C, where the duplex is presumably completely 
denatured; the C18 column afforded a near-baseline resolution of all six single-stranded 
siRNA compounds (two sense diastereomers and four antisense diastereomers) and the 
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phenyl column resolved four out of the six single-stranded compounds.  In contrast, the 
cyano column provided a much poorer separation, with broad and overlapping peaks. 
Comparing the results in Figures 3.2a and 3.2b, the cyano column appears to be better 
suited to resolving siRNA duplex diastereomers, whereas the C18 and phenyl columns 
were more successful in resolving related single-stranded siRNA stereoisomers under a 
denaturing condition.   
The retention mechanism governing the separation of stereoisomers under an ion-
pair reversed phase separation conditions is not fully understood at this point.  The C18 
column, which is the most non-polar stationary phase in the series, provides the best 
resolution for siRNA stereoisomers at high column temperature (e.g., under a denaturing 
condition).  This suggests that a separation condition that promotes the hydrophobic 
interaction between the stereoisomers and the stationary phase is likely important for 
achieving good selectivity.  
  
a) 
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b) 
 
Figure 3.2 Effect of stationary phase chemistry and temperature on the separation of ion- 
pair reversed phase separation of siRNA stereoisomers.  
a) The column temperature @ 45 oC 
b) The column temperature @ 80 oC 
Conditions: Columns (150 x 2.1 mm) and oven temperature as indicated. Mobile phase 
A consisted of 0.2M triethylammonium acetate (TEAA, pH 7) in water, and mobile phase 
B was a mixture of 20% A and 80% ACN.   The initial gradient method was run from 6% 
to 14% of mobile phase B in 20 minutes, followed by a steeper gradient elution from 
14% to 30% of mobile phase B in 7 minutes.  The flow rate was 0.2 mL/minute and the 
injection volume was 2 µL, with UV absorbance detection at 260 nm.  The siRNA 
sample concentration was approximately 0.1 mg/mL prepared in 20 mM phosphate buffer. 
 
 
 
3.3.2 The impact of ion-pair reagents on the separation of siRNA diastereomers 
IP-RPLC incorporates a small hydrophobic organic amine in the mobile phase as 
an ion-pair reagent, which increases the bulk hydrophobicity of the otherwise highly 
hydrophilic RNAs, allowing retention on the reversed-phase column.  In addition, the 
hydrophobic portion of the ion-pair reagent also adsorbs onto the C18 stationary phase, 
providing a dynamic ion-exchange phase for retaining analytes with opposite charges.  
The structure of the ion-pair reagent has a significant influence on the separation of 
oligonucleotides. 
21, 22
  The polarity and hydrophobicity of the ion-pair reagent can 
modulate its dynamic interaction with the oligonucleotides and the stationary phase, 
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potentially impacting the retention of the analyte.  Figure 3.3a shows the overlaid 
chromatograms for the analysis of the siRNA duplex using ethylammonium acetate, 
diethylammonium acetate, and triethylammonium acetate, at a concentration of 0.02 M, 
on a C18 column stationary phase with a column temperature of 80 
o
C.  Additional ion-
pair reagents, such as tetramethylammonium acetate, propylammonium acetate, and 
dipropylammonium acetate, were also evaluated (results not shown).   The screening 
results suggested that TEAA provided the best separation of the related stereoisomers of 
the sense and antisense strands of the now-denatured siRNA duplex, while EAA and 
DEAA provided poor resolution of the same stereoisomers.  Additional experiments were 
performed to explore the impact of ion-pair reagent concentration for ethylammonium 
acetate (EAA, 0.02M to 0.04M), diethylammonium acetate (DEAA, 0.02M to 0.15M), 
and triethylammonium acetate (TEAA, 0.05M to 0.2M), respectively.  Due to limited 
miscibility between EAA or DEAA and acetonitrile, the upper limit of concentration was 
set at 0.04M and 0.15M, respectively.  Figure 3.3b, 3.3c and 3.3d showed the overlaid 
chromatographic traces for siRNA duplex at different concentrations for EAA, DEAA 
and TEAA.  The results show that TEAA achieved a baseline resolution for all six 
stereoisomers with concentration ranging from 0.05M to 0.2M.  In contrast, both EAA 
and DEAA failed to achieve satisfactory separation at the concentration ranges explored 
here.      
It is worth noting that TEAA, mixed with hexafluoro isopropanol (HFIP), has 
previously provided an effective separation of single-stranded oligonucleotides differing 
in sequence structure and length.
22
  Our results showed that TEAA is also an efficient 
ion-pair reagent for the separation of denatured siRNA duplexes.   The underlying 
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mechanism is not clear regarding the role of TEAA in separating siRNA stereoisomers.   
TEAA is more hydrophobic than the other ion-pair reagents studied here, which would 
imply that an ion-pair reagent, capable of promoting hydrophobic interaction between the 
stereoisomers and the stationary phase, favors the separation of the stereoisomers.   
Future studies should be performed to evaluate additional ion-pair reagents to understand 
the impact of their structure and hydrophobicity on siRNA stereoisomer separation.   
 
 
Figure 3.3a: Effect of ion-pair agent on the separation of the siRNA stereoisomers by IP-
RPLC.   
Conditions: UPLC column: BEH C18; column oven temperature: 80 
o
C.  The 
concentration of ion-pair reagents is 0.02 M (pH 7).  Other conditions as in Figure 3.2.   
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Figure 3.3b: Effect of ethylammonium acetate (pH 7) concentration on the separation of the 
siRNA stereoisomers by IP-RPLC 
 
 
Figure 3.3c: Effect of diethylammonium acetate (pH 7) concentration on the separation of the 
siRNA stereoisomers by IP-RPLC 
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Figure 3.3d Effect of triethylammonium acetate (pH 7) concentration on the separation 
of the siRNA stereoisomers by IP-RPLC 
 
3.3.3 The impact of organic modifier on the separation of siRNA diastereomers  
 
The siRNA duplex was analyzed using gradient elution, where ACN, MeOH, 
THF and IPA were evaluated as organic modifiers in the mobile phase.  All organic 
modifiers have some polarity, making them water soluble.  The organic solvent imparts 
hydrophobicity to the mobile phase, which impacts the separation of the oligonucleotide.  
As shown in Figure 3.4, the use of ACN resulted in a marked improvement in the 
separation of the sense and antisense diastereomers relative to MeOH.  Poor separations 
were obtained using mobile phases with IPA or THF (data not shown).  The overall 
retention time with ACN as organic modifier is significantly shortened when compared 
with that of MeOH, reflecting the fact that ACN is a stronger solvent than MeOH for 
reversed-phase separations.  
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Figure 3.4: Effect of the organic modifier on the separation of siRNA stereoisomers by 
reversed-phase ion-pair chromatography.  
Conditions:  Column and oven temperature as in Figure 3.3, other conditions as in in 
Figure 3.2.  
 
  
 
Double-stranded siRNA forms a duplex in an aqueous environment.  The binding 
force between the two strands is largely attributed to hydrogen bonding, hydrophobic and 
ionic interactions.   The separation conditions reported here calls for high column 
temperature (e.g., 80 
o
C) with inclusion of organic modifier in the mobile phase.  Under 
these conditions the siRNA duplex is denatured during the separation, i.e., the sense and 
antisense strands are dissociated from one another and are migrating down the column 
independently and with a reduced secondary structure.  In addition, it is possible that 
ACN is more effective in disrupting the siRNA duplex, hence improving the separation 
of the sense and antisense stereoisomers.  Solution calorimetry experiments showed that 
the siRNA duplex has a melting temperature of 57 
o
C in 0.1 M pH 7 TEAA buffer 
solution (Figure 3.5).  The melting temperature dropped to 53 and 48 
o
C, respectively, 
when the TEAA buffer solution contained 10% MeOH or ACN, supporting the 
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hypothesis that ACN is more effective in disrupting the interstrand interactions of the 
siRNA duplex.   
 
 
Figure 3.5 Differential Scanning Calorimetry (DSC) showing siRNA duplex mealting 
temperature in 0.1 M TEAA (pH 7) buffer  
 
 
 
3.3.4 Method optimization for the separation of siRNA stereoisomers 
 
The separation conditions were further optimized by evaluating the impact of 
column temperature (50 to 80 
o
C), the concentration of the TEAA ion-pair reagent (0.02 
to 0.5 M), the flow rate (0.16 to 0.22 mL/min), and the gradient steepness.  Figure 3.6 
shows the overlaid chromatograms with column temperatures of 60, 70 and 80 
o
C, 
suggesting that a high temperature above the melting temperature of the siRNA favors 
stereoisomer separation.  Clearly, chromatographic resolution of diastereomeric 
phosphorothioates within single strands, as opposed to duplex siRNA structures, seems to 
be preferred. The separation was also evaluated at different concentrations of the ion-pair 
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agent, and 0.1 M TEAA was selected as the optimal concentration.  The flow rate and 
gradient steepness were then fine-tuned to further optimize the resolution of all species.  
The optimized conditions enabled a baseline resolution of all components as shown in 
Figure 3.7.  The limit of detection (LOD) for the final method was determined by 
injecting a series of low level siRNA sample solutions.  The LOD was estimated to be 4.2 
ng with UV absorbance detection at 260 nm. 
 
 
 
Figure 3.6 Effect of column temperature on the separation of siRNA stereoisomers   
Conditions: UHPLC column: BEH C18; Column oven temperature as indicated in the 
legend, other conditions as in Figure 3.2.  
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Figure 3.7 Optimized separation of the stereoisomers of the sense and antisense strands 
of siRNA using ion-pair UHPLC 
Final conditions: Column and oven temperature as in Figure 3.3; Mobile phase A is 
0.1M TEAA; The gradient elution program was from 6% to 12%B in 19.5 minutes, 
followed by steeper gradients of 12% to 14%B and 14 to 30%B in 5.5 minutes and 7 
minutes, respectively.  Other conditions as in Figure 3.2.   
 
 
 
3.3.5 Separation of desulfurization products of siRNA stressed with Iodine             
Iodine is known to induce a desulfurization reaction in oligonucleotide 
phosphorothioates without incurring other unwanted reaction products, thereby 
converting the stereoisomerically complex phosphorothioates into a single 
phosphodiester linked species. 
23
  Desulfurization of the siRNA duplex was performed by 
stressing the aqueous sample solution in a dilute (e.g., 0.03mM) iodine solution for one 
hour at an ambient condition.  The sample was then analyzed by IP-RP UHPLC to 
monitor the potential desulfurization of the phosphorothioate group in the siRNA.  Figure 
3.8 shows the overlaid chromatograms of siRNA control and the stressed sample.  A total 
of six degradation products were resolved from the parent siRNA stereoisomers, 
presumably due to a partial desulfurization reaction.  
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Figure 3.8 Oxidation of siRNA duplex by iodine 
Conditions: Column and oven temperature as in Figure 3.3, other conditions as in in 
Figure 3.2.  
  
 
 
3.4 Conclusions 
 
A reversed-phase ion-pair chromatography method was developed for the 
baseline separation of multiple stereoisomers of a double-stranded siRNA containing 
three phosphorothioate modification sites.  Key chromatographic parameters relevant to 
diastereomer separation included the structure of the ion-pair reagent, the organic 
modifier, and the chemistry of the stationary phase.  Separation conditions that promote a 
hydrophobic interaction between the analyte and the stationary phase appear to be critical 
to separating closely related siRNA stereoisomers.  Together with BEH C18 as the 
stationary phase and acetonitrile as the organic modifier, TEAA provided a superior 
separation efficiency and selectivity than its structural analogs, such as EAA, DEAA or 
TMAA.   ACN is a key component that facilitates diastereomer separation, while other 
organic modifiers, including MeOH, THF or IPA, failed in this aspect.  Solution-state 
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differential scanning calorimetry analysis of siRNA suggested that ACN can effectively 
disrupt the self-association of siRNA double strands, which appeared to be important to 
stereoisomer separation.  The optimized separation method was applied to a siRNA 
sample deliberately stressed with an iodine solution to induce desulfurization, where up 
to six degradation products were resolved from the parent siRNA stereoisomers.    
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Chapter 4 Simultaneous separation of small interfering RNA and phospholipids in 
lipid nanoparticle formulations 
 
4.1 Introduction  
 
Small interfering RNA (siRNA)-based therapeutics have several advantages 
compared to gene therapy, protein, and small molecule-based drugs owing to the direct 
interference with protein translation.  The key advantage of siRNA-based drugs is that 
siRNA catalytically degrades mRNA, hence suppressing harmful proteins implicated in 
disease before they are made.  Furthermore, siRNA is easy to design and has the potential 
of engaging a broader range of targets than traditional therapeutics. 
1,2,3 
Many delivery 
systems have been explored in the past, including lipid nanoparticles (LNP), polymer 
conjugates, and siRNA single chemical entities. 
4,5,6,7 
Among the various delivery systems, 
the lipid nanoparticle formulation has been the most extensively studied platform.  It 
represents an important formulation strategy for siRNA therapeutics with the potential to 
overcome the delivery barriers.  With particle size less than 100 nm, a fully assembled 
LNP typically contains siRNA, cationic lipids, phospholipids, PEG-containing short-
chain lipids, and cholesterol.  The cationic lipids are the most critical components in the 
LNP for modulating the cell uptake of siRNA.  They directly influence siRNA 
encapsulation efficiency, the particle size, and surface charge of LNPs, which are critical 
parameters for siRNA delivery to cell cytoplasm. 
8
 The lipid bilayers contain a minor 
component of a PEGylated short-chain lipid decorated on the bilayer surface.  The 
PEGylated short-chain lipid improves the physical stability of LNPs in systemic 
circulation upon intravenous (IV) injection, preventing particle aggregation in plasma. 
9
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Chemical analysis of LNPs is routinely performed during formulation 
development.  Quantification of each component in an LNP is important for ensuring a 
target potency of siRNA.  The desired lipid composition must be determined for the 
achievement of optimum physical properties, such as particle size, surface charge, etc.  
The analysis and control of low-level breakdown products from siRNA and lipids ensures 
that patients are not exposed to potentially harmful species. 
10,11,12
 
 Due to inherent differences in their chemical structure, polarity, and 
hydrophobicity, the separation and analysis of oligonucleotides or phospholipids in LNP 
formulations are typically performed with multiple HPLC methods.  Oligonucleotides are 
polyanionic at a pH range compatible with most stationary phases.  The separation modes 
for oligonucleotides analysis include ion-pair reverse phase HPLC, ion exchange 
chromatography, mixed-mode chromatography combining reversed-phase with ion 
exchange, and hydrophilic interaction chromatography. 
13,14,15,16 
Lipids have drawn renewed interest in recent years owing to its biological 
functions vital for energy storage, regulation of metabolic processes, cellular signaling, 
morphogenesis, secretion, and protein trafficking.  A comprehensive study of lipid 
species and their related networks has evolved into a significant scientific discipline – 
coined lipidomics.  This discipline is dedicated to understanding the role of lipids in 
regulating metabolic pathways in cells or other biologic systems. 
17,18
 The separation and 
characterization of lipids in biological samples present an unprecedented challenge to the 
analytical community due to their enormous molecular diversity.  Historically, the 
separation of lipids was achieved mainly by two separation modes - normal phase HPLC 
(NP-HPLC) and reverse phase HPLC (RP-HPLC). 
19,20,21,22,23,24
 The retention mechanism 
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on NP-HPLC is attributed to hydrophilic interactions between the polar groups of the 
lipids and the polar stationary phase, such as silica gel or polar bonded-phase derivatives 
thereof.  The lipids are separated according to the chemical structure of the polar 
functional groups, such as the headgroups, making NP-HPLC an effective method for 
separating lipids of different classes.  In contrast, RP-HPLC differentiates lipids based on 
their hydrophobicity defined by the alkyl chain length and degree of unsaturation of their 
tails as well as the charge state of the head groups.  The chromatographic analysis of 
lipids has an added technical challenge, relative to oligonucleotides, due to the lack of 
chromophores for UV detection.  Universal detectors, including the evaporative light 
scattering detector (ELSD) and the corona charged aerosol detector (corona CAD), are 
commonly used for lipid analysis. 
25,26 
UHPLC-mass spectrometry is another emerging 
technical field with significant advances in recent years for total lipid analysis and 
structure elucidation, with applications ranging from food analysis, quality control for 
cosmetics and pharmaceutical, as well as metabolic profiling. 
27
 
While there is a significant literature presence concerning the separation and 
analysis of oligonucleotides or lipids in their respective sample matrix, to the best of our 
knowledge there is no prior work on the simultaneous separation of siRNA and 
phospholipids in the context of an LNP delivery system.  A literature survey of separation 
techniques developed for oligonucleotides or phospholipids identified two separation 
modes with the potential for the simultaneous separation of siRNA, phospholipids, and 
their related species: ion-pair reversed-phase chromatography and mixed-mode 
chromatography.  Ion-pair reversed-phase HPLC has been extensively applied to 
oligonucleotide analysis.  The selectivity and retention characteristics of siRNA can be 
95 
 
modulated through careful selection of the ion-pair reagent, stationary phase, and organic 
modifier.  In contrast to the numerous reports for oligonucleotides, ion-pair reversed-
phase HPLC has fewer applications for lipid analysis largely due to their significant 
hydrophobicity.  One application involved the separation of phosphatidylinositol (PI) and 
its related molecular species using ion-pair reversed-phase HPLC, where 
tetrabutylammonium acetate was used as the ion-pair reagent.  The method was selective 
to anionic PI lipids with different degrees of unsaturation in the lipid chains.  Other 
studies showed that ion-pair RP-HPLC, coupled with ESI mass spectrometry, 
significantly improve method sensitivity for a range of trace level phospholipids. 
27
 
Mixed-mode chromatography is another separation technique with increasing 
popularity in biopharmaceutical applications owing to its unique selectivity and retention, 
often defined by a combination of hydrophobic, hydrophilic or ionic interactions.  Mixed-
mode chromatography with reversed-phase and ion-exchange retention characteristics, in 
theory, could accommodate the separation of analytes with orthogonal physical and 
chemical properties.  Key separation parameters relevant to the mixed-mode separation 
technique, incorporating both the reversed-phase and ion-exchange retention mechanisms 
into one integrated stationary phase chemistry, are fundamentally different from ion-pair 
reversed-phase HPLC.  For mixed-mode chromatography, the important factors 
influencing oligonucleotide separations include the type of counterion in buffers, the pH, 
and the ionic strength. 
In this chapter, an ion-pair reverse phase HPLC method, coupled with UV and 
corona charged aerosol detectors, was developed to separate a group of siRNA duplexes 
and phospholipids with significant diversity in physical and chemical properties.  We 
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elected to employ ion-pair reversed phase HPLC as our separation mode, owing to the 
tunable retention time for oligonucleotides, whose retention is primarily dominated by 
hydrophobic and electrostatic interactions.  The latter interaction between an 
oligonucleotide’s polyanionic phosphate moieties and the positively charged 
alkylammonium ions in the mobile phase reduced the polarity of the analyte, promoting 
hydrophobic interaction between the nitrogenous nucleobases and the stationary phase.  
Variation of the alkyl functional group of the ion-pair agent can further modulate the 
hydrophobic interaction.  Five different siRNA duplexes were used in the study.  The 
purpose of studying a small library of siRNAs was to create sufficient variation in the 
sample set so that the target separation method can be potentially used for the analysis of 
the LNP systems that contain multiple siRNAs for silencing various genes in the body. 
28
  
An LNP system is a multi-functional delivery vehicle, consisting of a range of 
lipids with different structural features.  To ensure the target method is suitable for 
separating lipids of various structures that can exist in an LNP, we selected six different 
lipids, of which five are zwitterionic phospholipids that vary in the alkyl chain length and 
the degree of unsaturation of the tail.  A cationic lipid was also included in the study.  
The selected lipids not only present a suitable matrix to developing a separation method, 
but it also allows us to study the retention behavior of the lipids under an ion-pair reverse 
phase separation conditions, which has not been systematically studied before in the 
literature.  We herein report an investigation of the influence of stationary phase 
chemistry, column temperature and the type and concentration of ion-pair reagent on the 
IP-RP UHPLC separation of both siRNA and phospholipids. 
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4.2 Material and methods  
4.2.1 Chemicals 
 
The siRNA duplex targeting ApoB gene (Zimmerman sequence) and four 
additional proprietary siRNA duplexes were provided by Merck Sharp & Dohme (MSD) 
RNA synthesis group.  Phospholipids of different chain length or headgroups were 
sourced from Avanti Polar Lipids (Alabaster, AL, USA).  The lipids are 1,2-dipalmitoyl-
sn-glycero-3-phosphocholine (DPPC), 1,2-dilauroyl-sn-glycero-3-phosphocholine 
(DLPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-didecanoyl-sn-glycero-
3-phosphocholine (DDPC), 1,2-dioleoyl-3-trimethylammonium-propane chloride salt 
(DOTAP), and dimyristoleoyl phosphocholine (DMPC).  Figure 4.1 shows the chemical 
structure of the phospholipids.  Ion-pair reagents were purchased from the following 
vendors: triethylammonium acetate buffer (pH 7, ~ 1.0 M in water) was obtained from 
Sigma-Aldrich (St. Louis, MO, USA), whereas dipropylammonium acetate (DPAA, 0.5 
M in water), dibutylammonium acetate (DBAA, 1M in water), and diamylammonium 
acetate (DAAA, 0.5M in water) were acquired from Fisher Scientific (Norristown, PA 
19403, USA).  HPLC grade acetonitrile (ACN) was obtained from Fisher Scientific.  
Experimental lipid nanoparticle (LNP) suspensions were provided by Merck Sharp & 
Dohme (MSD) Sterile formulation group.   The LNP formulation consisted of a 
proprietary siRNA duplex, two types of phospholipids, cholesterol and PEGylated short 
chain lipid.  
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Figure 4.1 Chemical structures of the lipids 
 
4.2.2  Instrument  
 
An Agilent 1290 Infinity UHPLC system (Agilent Technologies, Santa Clara, CA, 
USA) was employed for the separation of siRNA and phospholipids.  This UHPLC 
system consisted of a binary pump, a diode array detector (DAD), a corona charged 
aerosol detector (CAD), an autosampler and a column heater.  This system could be 
operated at a pressure up to 1200 bar.  Because the CAD is a destructive detector, it was 
connected in series and after the DAD.  Data collection rate was 5 Hz for the CAD.  The 
corona nebulizer was controlled at 35
o
C while the evaporator tube was kept at ambient 
temperature.  
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A differential scanning microcalorimeter (MicroCal, LLC, Northampton, MA, 
USA) was used to measure the melting temperature of the various siRNA duplexes.  The 
system can operate at a temperature range of -10° to 130° Celsius.  
4.2.3 Ion-pair reversed phase chromatographic conditions 
For the separation of siRNA and phospholipids, the samples were subjected to 
gradient elution using sub-2um UHPLC columns.  The columns studied in this work had 
the same dimensions (150 x 2.1 mm) and included the Acquity BEH phenyl, BEH C8, 
BEH C18, CSH fluoro-Phenyl, and HSS cyano. The nominal particle size of the 
stationary phase packings was 1.7 m, except for the HSS cyano, which had a particle 
size of 1.8 µm.  Mobile phase A consisted of aqueous solutions of ion-pair reagents, and 
mobile phase B was pure ACN.  The initial gradient method was run from 10% to 35% B 
in 15 minutes, followed by a steeper gradient elution from 35% to 100 %B in 15 minutes 
and an isocratic hold at 100% B for 10 minutes.  The siRNA samples were prepared in 20 
mM phosphate buffer (pH 7) at a concentration of approximately 0.1 mg/mL.  The 
phospholipids were dissolved in ethanol at a concentration of approximately 0.3 mg/mL.  
For siRNA analysis in the LNP formulation, an aliquot the LNP suspension (100 
uL) was transferred to a 1.5-mL centrifuge tube.  600 μL of ethanol was then added to the 
centrifuge tube with a calibrated micropipette.  The mixture of the LNP suspension and 
ethanol was mixed by inverting the test tube for at least three times, followed by 30-
second vortex mixing.  An additional 600 μL of ethanol was added to the tube, and the 
sample was mixed by inversion and vortex mixing.  The sample tube was centrifuged at 
14,000 RPM for 10 minutes.  The supernatant was discarded from the tube using a glass 
Pasteur pipette.  Care was taken to ensure the RNA pellet was not disturbed during the 
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supernatant removal process.  The residual ethanol from the pellet was evaporated by 
purging with nitrogen gas for about five minutes.  One microliter of 20 mM phosphate 
buffer solution was added to the dry pellet.  The dry pellet in the buffer solution was 
mixed with vortexing for 30 seconds to dissolve the dried pellet.  For lipid analysis in 
LNP formulation, about 100 uL of LNP suspension was transferred into a clean HPLC 
vial.  An aliquot of ethanol (1 mL) was added to the HPLC vial with a calibrated 
micropipette, and the sample solution was mixed by vortexing for 30 seconds. 
4.2.4 Differential scanning calorimetry method condition  
The melting temperature (Tm, or dissociation temperature) of the siRNA duplexes 
were measured using capillary cell micro-calorimetry.  A 0.1 - mg/mL siRNA sample 
solution was prepared in phosphate buffer solution at pH 7.  The sample solutions were 
added to a 96-well plate and automatically applied to the sample capillary of which the 
run sequence was controlled.  The heating and cooling cycle from 5
o
C to 110
 o
C was 
applied to both the reference and sample cells with a scan rate of 1 ˚C/minute.  Each 
sample was run in two replicates.   The difference between the melting temperatures from 
the two replicates is typically within 1 
o
C.   
 
4.3 Results and Discussion 
 
4.3.1 Initial assessment of ion-pair reversed phase method for simultaneous 
analysis of siRNA duplexes and phospholipids 
Ion-pair reversed-phase HPLC has the potential to reduce the retention time gap 
between siRNA and phospholipids owing to the versatility of the ion-pair reagent.  
Figure 4.2a and 4.2b show the results of our initial attempt to simultaneously separate 
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five siRNA duplexes and six lipids using ion-pair reverse phase chromatography with 
dual detectors – a diode array absorbance detector for the siRNAs and a charged aerosol 
detector (CAD) for the lipids.  With 100mM TEAA in the aqueous component of the 
mobile phase, the retention time of siRNA duplexes ranged from 2.8 to 7 minutes, which 
represents 15 to 22% ACN in mobile phase as the siRNAs exited the column.  Most of 
the phospholipids (DDPC, DLPC, DMPC, and DPPC) eluted between 26 and 32 minutes, 
corresponding to 83% and 100% ACN in the mobile phase.  The percentage of strong 
solvent needed to elute the lipids is about 4- to 5-fold higher than that for the siRNAs due 
to their significant difference in hydrophobicity.  DOPC and DOTAP are structurally 
different lipids with zwitterionic and cationic head groups, respectively.  Neither was 
eluted on the C18 column under these separation conditions.  The large retention gap 
between the siRNAs and lipids on the BEH C18 column with 0.1 M TEAA was not 
unexpected as the polarity of the two classes of molecules is very different from each 
other.  The initial separation results highlighted the challenges of developing a unified 
separation method capable of simultaneously separating both siRNAs and lipids with a 
minimal retention gap.  The remaining portion of this study will focus on the 
investigation of the influence of stationary phase chemistry, column temperature, and the 
type of the ion-pair reagent on the IP-RPLC separation of both siRNA and lipids.  
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 a) 
 
b) 
 
Figure 4.2 UHPLC-UV-CAD separation and detection of siRNA duplexes and 
phospholipids using TEAA as the ion-pair reagent on a BEH C18 column.  
a) Overlaid chromatographic traces for the siRNA duplexes with UV detection at 260 nm. 
b) Overlaid chromatographic traces for the phospholipids with corona CAD detection 
Conditions: UPLC column: BEH C18 (150 x 2.1 mm). Column oven temperature: 50 
o
C. 
Mobile phase A consisted of 0.1M triethylammonium acetate (TEAA, pH 7) in water, 
and mobile phase B was ACN.  The gradient method was run from 10% to 35% B in 15 
minutes, followed by a steeper gradient elution from 35% to 100 %B in 15 minutes and 
an isocratic hold at 100% B for 10 minutes.  The flow rate was 0.4 mL/minute and the 
injection volume was 5 µL. A diode array detector, with UV absorbance detection at 260 
nm, was used to monitor siRNA and a corona CAD was used for phospholipids.  The 
siRNA sample concentration was approximately 0.1 mg/mL prepared in 20 mM 
phosphate buffer.  The lipid concentration was about 0.3 mg/mL.  
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4.3.2 The impact of stationary phase chemistry on the separation of siRNA 
duplexes and phospholipids 
Acquity BEH, CSH and HSS UHPLC columns of different stationary phase 
chemistry, including C18, C8, cyano, phenyl, and fluoro-phenyl, were investigated for 
the separation of siRNA duplexes and phospholipids.  The UHPLC separation was 
performed at 50 
o
C, which is below the dissociation temperature of the siRNA duplexes 
measured in an aqueous medium (Refer to Section 4.3.4 for the DSC data).  Figures 4.3 
to 4.6 show the overlaid chromatographic traces for the analysis of the siRNA duplex and 
phospholipids on various UHPLC columns.  The retention time for siRNA duplex ranged 
from 0.8 to 4.5 minutes, 1.5 to 6 minutes, 3 to 6.5 minutes, 3 to 8 minutes and 4 to 8 
minutes using the cyano, C8, C18, fluoro-phenyl and phenyl columns, respectively.  The 
results are to a certain degree unexpected.  We anticipated that the siRNAs should have a 
longer retention time on a C18 column than the other stationary phases due to a stronger 
hydrophobic interaction between the analytes and the non-polar, C18 stationary phase.  
Instead, our data showed that the siRNAs are more retentive on the fluoro-phenyl or 
phenyl columns than the other ones, presumably due to a specific π- π interaction 
between the phenyl groups on stationary phase and the nucleobases of the siRNAs, in 
addition to hydrophobic interactions.  The peak shape for the siRNA duplexes is complex 
both in terms of the number of peaks observed and their asymmetric feature.  The siRNA 
duplexes studied here contained phosphorothioate stereocenters, which together with the 
stereocenters on the ribose sugar, results in siRNA stereoisomers that are partially 
resolved at temperatures below their dissociation temperature.  The presence of 
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stereoisomers may explain the complex peak shape observed.  Efforts to improve siRNA 
peak shape will be discussed later in this chapter.  
The retention behavior of the phospholipids under ion-pair reversed-phase HPLC 
is relatively predictable and appears to be consistent with the retention mechanism of a 
traditional reversed-phase HPLC, with hydrophobic interactions as the dominant feature.  
As expected, the retention time of each lipid slightly increased as the alkyl chain length 
on the stationary phase increased from propyl for the fluoro-phenyl column to octadecyl 
for the C18 column.  In addition, the elution order of the phospholipids remained the 
same regardless of the stationary phase chemistry, which is also consistent with our 
expectation for a retention process that is dominated by a hydrophobic interaction 
between the analytes and the stationary phase.  We anticipate that the alkyl chain length 
of the lipid tail will determine the retention time.  Indeed, the retention time of the lipids 
increased in the following order: DDPC (saturated C10) < DLPC (saturated C12) < 
DMPC (C14 with 2 double bonds) < DPPC (saturated C16) < DOPC (C18 with two 
double bonds) < DOTAP (C18 with two double bonds).   Although the alkyl chain length 
for both DOTAP and DOPC is the same, DOTAP is more hydrophobic than DOPC 
because a large portion of the molecule is hydrophobic and the phosphate group is 
missing.     
The strategy for simultaneous and efficient separation of siRNAs and lipids 
depends in part on identifying a stationary phase chemistry that minimizes the retention 
gap between the siRNAs and phospholipids, i.e., one that maximizes siRNA – stationary 
phase interactions while reducing hydrophobic lipid – stationary phase interactions.  The 
column screening showed that the fluoro-phenyl and phenyl phases, both having short 
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alkyl chain lengths, are the potential leads.  The BEH phenyl column was selected for 
further evaluation since the column can operate at high temperature (80 
o
C), while the 
temperature limit for the fluoro-phenyl column is only 60 
o
C.  As shown in section 3.4, 
the separation of siRNA duplexes at higher column temperature is often preferred to 
maintain a good peak shape.    
 
a) 
 
 
 
 
 
 
 
 
 
 
106 
 
b) 
 
Figure 4.3 UHPLC-UV-CAD separation and detection of siRNA duplexes and 
phospholipids using TEAA as the ion-pair reagent on a CSH fluoro-phenyl column. 
a) Overlaid chromatographic traces for siRNA with UV detection at 260 nm. 
b) Overlaid chromatographic traces for phospholipids with corona CAD detection 
Conditions: UPLC column: CSH fluoro-phenyl C18 (150 x 2.1 mm). Other conditions 
are as in Figure 4.2.  
 
 
a) 
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b) 
 
 
Figure 4.4 UHPLC-UV-CAD separation and detection of siRNA duplexes and 
phospholipids using TEAA as the ion-pair reagent on a HSS cyano column. 
a) Overlaid chromatographic traces for siRNA with UV detection at 260 nm. 
b) Overlaid chromatographic traces for phospholipids with corona CAD detection 
Conditions: UPLC column: HSS cyano (150 x 2.1 mm). Other conditions are as in 
Figure 4.2. 
 
 
 
 a) 
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b) 
 
 
 
 
Figure 4.5 UHPLC-UV-CAD separation and detection of siRNA duplexes and 
phospholipids using TEAA as the ion-pair reagent on a BEH phenyl column. 
a) Overlaid chromatographic traces for siRNA with UV detection at 260 nm. 
b) Overlaid chromatographic traces for phospholipids with corona CAD detection 
Conditions: UPLC column: BEH phenyl (150 x 2.1 mm). Other conditions are as in 
Figure 4.2.  
 
 
 
a) 
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b) 
 
Figure 4.6 UHPLC-UV-CAD separation and detection of siRNA duplexes and 
phospholipids using TEAA as the ion-pair reagent on a BEH C8 column. 
a) Overlaid chromatographic traces for siRNA with UV detection at 260 nm. 
b) Overlaid chromatographic traces for phospholipids with corona CAD detection 
Conditions: UPLC column: BEH C8 (150 x 2.1 mm). Other conditions are as in Figure 
4.2. 
  
 
 
4.3.3 The impact of ion-pair reagents on the separation of siRNA duplexes and 
phospholipids 
In IP-RPLC, oligonucleotides are retained and separated through ion-pair 
formation between the protonated hydrophobic organic amine (i.e., the ion-pair reagent) 
in the mobile phase and the negatively charged analyte, followed by partitioning of the 
complex into reversed-phase stationary phase.  In addition, the hydrophobic ion-pair 
reagent can adsorb onto the stationary phase, exhibiting a dynamic ion-exchange 
retention mechanism for analytes of opposite charges.  Aside from stationary phase 
chemistry, the chemical nature of the ion-pair reagents, specifically their hydrophobicity 
and the degree of substitution at the amine group by short alkyl chains, can influence the 
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separation of oligonucleotides. 
29, 30
  Figures 4.7 to 4.9 show the overlaid chromatograms 
for the analysis of the siRNA duplexes and phospholipids with a BEH phenyl column and 
DPAA, DBAA and DAAA as the ion-pair reagents, respectively.  The overall separation 
results showed that the retention time of the siRNA duplexes is in the range of 7 to 12 
minutes, 16 to 20 minutes and 22 to 25 minutes for DPAA, DBAA, and DAAA.  The 
increase in siRNA retention time as a function of hydrophobicity of the ion-pair reagent 
is as expected and consistent with the retention mechanism described earlier in this 
section.  Furthermore, we plotted the natural logarithm of the retention factor (k) for each 
siRNA sample as a function of the number of carbons in the ion-pair reagent.  Figure 
4.10 shows a typical plot for Zimmerman siRNA; Table 4.1 summarizes the retention 
factor for the entire sample set as well as the correlation coefficient for linear regression 
of the individual plot.  TEAA was not included in the group since it is a structural isomer 
of DPAA and does belong to the homologous series.  The data analysis suggested that Ln 
k (retention factor) of the siRNA has a linear relationship with the number of the carbons 
in the alkyl chains.  The same trend was observed for the ion-pair reagents when they 
were injected as samples and separated using a mobile phase that is free of any ion-paring 
species.  This observation suggested that the retention of siRNA duplex is largely 
dominated by the partitioning of the alkyl chains in the ion-pair reagents between the 
mobile phase and stationary phase.  The partitioning process in reversed phase separation 
obeys the law of thermodynamics (refer to eqn. (1.14) in Chapter 1) where the Ln K (K - 
partition coefficient) has a linear relationship with the free energy associated with 
transferring the molecules from the mobile phase to the stationary phase.     
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In contrast to siRNA duplexes, the retention time of each lipid varied slightly as 
the ion-pair reagent was changed.  The lack of impact of the ion-pair reagent on the lipid 
separation is an interesting observation, and this could be rationalized by proposing a 
partitioning process as the primary mode of separation mechanism for the lipids, where 
hydrophobic interactions between the stationary phase and the lipid’s alkyl chain are 
dominant.  Ion-pair reagents are not expected to promote additional interaction between 
zwitterionic or cationic lipids and a reversed-phase stationary phase.  Furthermore, we 
observed that the retention time of the lipid increased as the alkyl chain length increased 
regardless the type of ion-pair reagent.   This again is consistent with the retention 
mechanism of the hydrophobic lipids under s reversed-phase separation conditions.  
Comparing the overall separation outcome for siRNA duplexes and phospholipids, 
DBAA and DAAA are the lead candidates that significantly reduce the retention gap, 
making simultaneous separation possible for these two classes of biomolecules with 
orthogonal physical and chemical properties.  We further selected DBAA over DAAA 
based on (i) a reduced impurity level in the reagent and (ii) the quality of the baseline 
during separation of siRNA duplex with UV as detection. 
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a) 
 
 
b) 
 
Figure 4.7 UHPLC-UV-CAD separation and detection of siRNA duplexes and 
phospholipids with DPAA as the ion-pair reagent on a BEH phenyl column. 
a) Overlaid chromatographic traces for siRNA with UV detection at 260 nm. 
b) Overlaid chromatographic traces for phospholipids with corona CAD detection 
Conditions: Mobile phase A consisted of 0.1 M DPAA.  UPLC column: BEH Phenyl 
(150 x 2.1 mm). Other conditions are as in Figure 4.2.  
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a) 
 
 
 
b) 
 
Figure 4.8 UHPLC-UV-CAD separation and detection of siRNA duplexes and 
phospholipids with DBAA as the ion-pair reagent on a BEH phenyl column 
a) Overlaid chromatographic traces for siRNA with UV detection at 260 nm. 
b) Overlaid chromatographic traces for phospholipids with corona CAD detection 
Conditions: Mobile phase A consisted of 0.1 M DBAA.  UPLC column: BEH phenyl 
(150 x 2.1 mm); other conditions are as in Figure 4.2.  
 
114 
 
 
Figure 4.9 UHPLC-CAD separation and detection of phospholipids with DAAA as the 
ion-pair reagent on a BEH phenyl column 
Conditions: Mobile phase A consisted of 0.1 M DAAA.  UPLC column: BEH phenyl 
(150 x 2.1 mm); other conditions are as in Figure 4.2.  
 
 
 
 
 
 
 
Figure 4.10 A representative plot showing the Ln k of Zimmermann siRNA as a function 
of the number of carbons in ion-pair reagents 
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Table 4.1 Summary of the retention factor for various siRNA samples and the correlation 
coefficient for Ln k vs the number of carbons plots 
 
 
 
Note: The retention factor was reported as an average of two replicate injections except 
for DEAA where the measurement was based on a single injection.  
 
 
 
4.3.4  The impact of column temperature on the peak shape of siRNA sample 
With DBAA identified as the lead ion-pair reagent, we next explored column 
temperature to improve the peak shape for siRNA duplexes.  As shown in Figure 4.8a 
(with a column temperature of 50 
o
C), the Zimmermann duplex is the only sample for 
which baseline resolution between the two single strands could be achieved, one eluting 
as a single peak and the other as a partially resolved doublet.  Samples siRNA 1 and 
siRNA 2 exhibited a single peak with a poor resolution between the two strands, while 
siRNA 3 and siRNA4 showed a broad peak shape with no resolution between the two 
complementary strands.   
The column temperature is expected to impact the peak shape of the siRNA 
duplex.  The peak shape of a duplex can undergo two transitions as the column 
temperature increases within a range that covers the melting temperature of a double-
stranded siRNA.  In its native conformation, the duplex adopts a double-helix structure 
with the two strands strongly associated primarily through hydrogen bond interaction.  If 
the column temperature is below the melting temperature, the siRNA duplex will elute as 
                                 Retention factor
Ion pair reagent 
The number 
of carbons 
Zimmermann 
siRNA siRNA 1 siRNA 2 siRNA 3 siRNA 4
DEAA 4 3.9 7.2 5.7 5.0 5.8
DPAA 6 7.8 12.8 9.7 10.9 12.6
DBAA 8 18.4 22.0 19.6 19.9 21.5
DAAA 10 27.8 29.1 26.9 27.8 29.3
Correleration coefficient 0.97 0.97 0.97 0.96 0.96
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a single peak.  As the column temperature increases and approaches the onset melting 
temperature of the duplex, the siRNA could be a mixture of several closely related 
species in equilibrium with each other, including the denatured single strands, the intact 
duplex, and their respective stereoisomers.  The complex sample mixture can result in 
poor peak shapes due to insufficient resolution of the components and where the 
equilibrium kinetics are slow, the latter of which is often the case for biological 
macromolecules. 
31
  When the column temperature exceeds the melting temperature, 
siRNA duplexes can undergo rapid melting upon injection onto the column and then elute 
as sharp single-stranded peaks.
32
  
To improve the peak shape of a siRNA duplex, we need to set the column 
temperature either below the onset melting temperature of or above the peak melting 
temperature of the sample.  First, we utilized solution differential scanning calorimetry 
(DSC) to assess the melting temperature of the siRNA duplexes.  Figure 4.11 shows the 
overlaid DSC thermograms for five different siRNA duplexes.  The respective onset 
melting temperatures were 53 ˚C, 56 ˚C, 70 ˚C, 75 ˚C and 85 ˚C for the Zimmerman 
siRNA and siRNAs 1 through 4.  The measured melting temperatures in phosphate buffer 
solution were 60
 ˚C, 95 ˚C, 64 ˚C, 76 ˚C and 82 ˚C for the Zimmerman siRNA and 
siRNAs 1 through 4, respectively.  Next, we attempted to separate the siRNA duplexes at 
temperatures ranging from 40 to 70˚C to verify how the column temperature impact the 
peak shape; the results are shown in Figure 4.12 (a-e).  
The impact of column temperature on the peak shape of siRNA duplex is complex 
and intriguing.  For the siRNA duplex with the Zimmermann sequence (Figure 4.12a), 
the two complementary strands were well separated over the entire temperature range.  
117 
 
This implies that the Zimmermann duplex underwent on-column melting at a temperature 
(e.g., 40 ˚C or lower) significantly below the measured on-set melting temperature of 53 
˚C (in phosphate buffer).  The on-column melting temperature depression is likely due to 
the presence of an organic solvent (e.g., ACN) in the mobile phase and/or the pressure-
induced shear stress.  The later eluting strand shows a doublet peak shape, which is 
attributed to the partial resolution of diastereomers. 
33
  Since the partial resolution of 
diastereomers negatively impacts siRNA peak shape, it is desirable to eliminate the 
separation of diastereomers during the analysis of siRNA duplexes and the potential low-
level impurities by UHPLC.  Hexafluoroisopropanol (HFIP) has been reported in the 
literature as an effective organic additive to inhibit the separation of diastereomers of 
phosphorothioate oligonucleotides on achiral columns by reducing the hydrophobic 
interaction between oligonucleotide and the stationary phase. 
30
 Indeed, the addition of 
0.1M HFIP in mobile phase A (i.e., 0.1M DBAA, pH 7) improved the peak shape for 
Zimmermann siRNA under denaturing conditions, where the duplex eluted as two 
symmetrical single-stranded peaks.  (Figure 4.13)  
For siRNA 1 (Figure 4.12b), the duplex remained a single peak with a slight 
partial resolution of the two strands at a temperature from 40 to 60 ˚C.  The peak shape 
showed a sharp transition as temperature increased from 60 to 70 ˚C.  Significant peak 
broadening at 70 ˚C suggested the column temperature is approaching the on-column 
melting temperature for siRNA 1, which once again is lower than in PBS buffer (e.g., an 
onset temperature of 85 
o
C) as acetonitrile in the mobile phase and/or pressure-induced 
shear stress during elution could lower the melting temperature.  The column temperature 
for siRNA 1 should thus be kept below 70 ˚C to avoid this peak broadening effect.  The 
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asymmetric peak shape at temperatures below 70 ˚C can be improved by adding 0.2M 
HFIP into the mobile phase A, where the duplex eluted as a single, symmetric peak (data 
not shown).  
The change of peak shape as a function of column temperature is similar for 
siRNA 2 and 3 (Figure 4.12c and d).  In both cases, the siRNA duplex showed a broad 
and asymmetric peak shape at 40 
o
C.  The peak width narrowed as the temperature 
increased, and the siRNA sample exhibited a single, symmetric peak at 70 ˚C.  
Significant peak broadening at 40 
o
C for both siRNA 2 and 3 suggested that the column 
temperature at this point started to approach the onset melting temperature for both RNA 
duplexes on the column.   This was confirmed by conducting additional separations at 
lower column temperatures, such as 20 or 30 
o
C, which revealed a sharp transition in 
peak width as the temperature increased from 20 to 30 
o
C for siRNA 2 and 30 to 40 
o
C 
for siRNA 3, respectively.   In contrast to siRNA 1, the ideal column temperature for 
siRNA 2 and 3 is around 70 ˚C.  Higher temperatures (> 70 oC) were not evaluated due to 
concerns over column instability.    
The temperature dependent peak shape for siRNA 4 (Figure 4.12e) showed two 
distinct transition temperatures.  The peak width significantly narrowed as the column 
temperature was increased from 60 to 70 ˚C (which is consistent with those for siRNA 2 
and 3) and broadened as it was increased from 40 to 50 ˚C, respectively.  The transition at 
the low-temperature end corresponded to the onset of on-column melting of siRNA 4 
duplex and the transition at high temperature was related to complete on-column melting.  
Similar to siRNA 2 and 3, a column temperature of 70 
o
C is preferred for duplex 
quantitation as the siRNA eluted as a single, slightly asymmetric peak.  Table 4.2 
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summarizes the general recommendations on mobile phase A composition and column 
temperature for direct analysis of siRNA duplex.  It is worth noting that while the column 
temperature has a significant impact on the retention time and peak shape for siRNA, it 
has little influence over the separation of phospholipids using ion-pair reverse phase 
method (data not shown).   
  
 
 
Figure 4.11 Overlaid DSC thermograms for a series of siRNA duplexes 
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Figure 4.12a Effect of column temperature on the separation of Zimmermann siRNA 
duplex. 
Conditions: Mobile phase A consisted of 0.1 M DBAA.  UPLC column: BEH phenyl 
(150 x 2.1 mm); other conditions are as in Figure 4.2.  
 
 
 
 
 
Figure 4.12b Effect of column temperature on the separation of sRNA 1 duplex  
Conditions: Mobile phase A consisted of 0.1 M DBAA.  UPLC column: BEH phenyl 
(150 x 2.1 mm); other conditions are as in Figure 4.2.  
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Figure 4.12c: Effect of column temperature on the separation of siRNA 2 duplex. 
Conditions: Mobile phase A consisted of 0.1 M DBAA.  UPLC column: BEH phenyl 
(150 x 2.1 mm); other conditions are as in Figure 4.2.  
 
 
 
 
 
Figure 4.12d Effect of column temperature on the separation of siRNA 3 duplex 
Conditions: Mobile phase A consisted of 0.1 M DBAA.  UPLC column: BEH phenyl 
(150 x 2.1 mm); other conditions are as in Figure 4.2.  
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Figure 4.12e Effect of column temperature on the separation of siRNA 4 duplex 
Conditions: Mobile phase A consisted of 0.1 M DBAA.  UPLC column: BEH phenyl 
(150 x 2.1 mm); other conditions are as in Figure 4.2.  
 
 
 
 
 
Figure 4.13 The impact of HFIP in mobile phase A on the peak shape of Zimmermann 
siRNA  
Conditions: Mobile phase A consisted of 0.1 M DBAA and 0.1 M HFIP.  UPLC column: 
BEH phenyl (150 x 2.1 mm); other conditions are as in Figure 4.2.  
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Table 4.2 Summary of recommended mobile phase A compositions and column 
temperatures for various siRNA duplexes 
Sample ID Mobile phase A  
Column 
Temperature 
Zimmermann siRNA  
0.1 M DBAA/0.1 M 
HFIP 40 to 60
 o
C  
siRNA 1 
0.1 M DBAA/0.2 M 
HFIP 60
 o
C  
siRNA 2 0.1 M DBAA 70 
o
C  
siRNA 3 0.1 M DBAA 70
 o
C  
siRNA 4 0.1 M DBAA  70
 o
C  
 
 
 
4.3.5 Separation of siRNA and lipids in LNP formulation with ion-pair reverse 
phase UHPLC  
The UHPLC method discussed in the previous sections can be further optimized 
concerning the gradient condition to reduce the runtime.  Figure 4.14 shows a 
representative chromatogram of siRNA samples and phospholipids in a 25-minute 
gradient method, demonstrating an adequate separation of the entire sample set with good 
selectivity.  The peak shapes for DOTAP and siRNA 4 are broad, and their root causes 
are likely different.  The broad peak shape for DOTAP, a cationic lipid bearing a positive 
charge at neutral pH (or the pH of the mobile phase), is likely due to a secondary 
interaction (e.g., electrostatic interaction) between the stationary phase and the analyte.  
The peak broadening for siRNA 4 can be attributed to the column temperature that is 
close to the onset melting of the duplex.  Additional studies are needed to optimize the 
separation conditions in order to improve the peak shape for DOTAP and siRNA 4 while 
maintaining the separation of the rest of siRNAs and lipids.    
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Figure 4.14 UHPLC-UV-CAD separation and detection of siRNA duplexes and 
phospholipids with DBAA as the ion-pair reagent on a BEH phenyl column 
c) Overlaid chromatographic traces for siRNA with UV detection at 260 nm. 
d) Overlaid chromatographic traces for phospholipids with corona CAD detection 
Conditions: Mobile phase A consisted of 0.1 M DBAA.  UPLC column: BEH phenyl 
(150 x 2.1 mm); column temperature: 70 
o
C. The gradient method was run from 30% to 
35% B in 5 minutes, followed by a steeper gradient from 35% to 100% B in 10 minutes 
and isocratic hold at 100% B for 5 minutes.  Other conditions are as in Figure 4.2.  
 
The ion-pair reversed phase methods (both the short and long gradient) were 
applied to the analysis of an experimental LNP formulation that consisted of a double-
stranded siRNA, two types of phospholipids, cholesterol and PEGylated short-chain lipid.  
Figure 4.15 shows the chromatographic traces of all key components in the formulation 
using UV and corona-CAD dual detectors.  Forced stressed testing with base (e.g., 0.01 
M NaOH) and 0.3% hydrogen peroxide suggested that siRNA is more stable than the 
lipid components.  The fact that the siRNA is more stable than the lipids is not surprising 
as the siRNA has been chemically modified to prevent hydrolysis in an aqueous 
environment.  Whereas the siRNA was stable with respect to base stress, one minor 
degradation product (~18 minutes) was detected when stressed with hydrogen peroxide, 
presumably due to the desulfurization of the siRNA that contains phosphorothioate 
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linkage.  The lipid components are susceptible to hydrolysis and oxidation.  Under 
ambient conditions, lipid 1 and PEGylated lipid underwent complete hydrolysis within 60 
minutes in the presence of 0.01M NaOH.  Lipid 2 and cholesterol are stable with respect 
to base hydrolysis, but lipid 2, when stressed with hydrogen peroxide, can form an 
oxidative product with a retention time close to 30.6 minutes.   Figure 4.16 shows the 
stacked chromatograms for both siRNA and lipids components with gradient elution, 
achieving an analysis time of less than 20 minutes and demonstrating good selectivity for 
all key ingredients in LNP.  
  
a) 
 
b).  
 
Figure 4.15 UHPLC-UV-CAD separation and detection of siRNA duplex and lipid 
vehicles in the LNP formulation 
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Figure 4.15 (cont’d) 
a).Chromatogram of siRNA in LNP with UV absorbance detection at 260 nm. 
b).Chromatogram of lipids in LNP with corona CAD detection 
Conditions: Mobile phase A consisted of 0.1 M DBAA and 0.1 M HFIP.  UPLC column: 
BEH phenyl (150 x 2.1 mm); other conditions are as in Figure 4.2.  
 
 
Figure 4.16 UPLC analysis of the LNP formulation with UV and CAD as dual detectors 
Conditions: Mobile phase A consisted of 0.1 M DBAA.  UPLC column: BEH phenyl 
(150 x 2.1 mm).  The gradient method was run from 35% to 100% B in 10 minutes, 
followed by an isocratic hold at 100% B for 5 minutes.  Other conditions are as in Figure 
4.2.  
 
 
4.4 Conclusions  
 
A reversed-phase ion-pair chromatography method was developed for the 
simultaneous separation of multiple siRNA duplexes and phospholipids, the main 
components of the lipid nanoparticle formulation.   Key chromatographic parameters 
critical to reducing the retention gap between hydrophilic siRNA and hydrophobic 
phospholipids included the chemistry of the stationary phase and the structure of the ion-
pair reagent.  With BEH phenyl as the stationary phase and ACN as the organic modifier 
in the mobile phase, ion-pair reagent dibutylammonium acetate (DBAA) provided a 
superior separation efficiency and selectivity compared to other structural analogs, such 
as TEAA, DPAA, and DAAA.  The column temperature has a significant impact on the 
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peak shape of double-stranded siRNA; the selection of column temperature depends on 
the on-column melting temperature of the siRNA duplex.  A temperature range covering 
both the onset and peak melting temperature of the siRNA should be avoided in order to 
maintain a good peak shape.    
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  Chapter 5 Separation and stability evaluation of siRNA duplex under forced stress 
conditions 
 
5.1 Introduction 
Native RNA is highly susceptible to enzymatic degradation by ribonucleases and 
non-enzymatic hydrolysis by acid or base. 
1,2
  Synthetic siRNAs often incorporate 
chemically modified nucleotides to improve in vivo serum stability.  Chemical 
modification of siRNA includes the replacement of 2’-hydroxyl group of the ribose with 
fluorine or methoxy.  In addition, the 3’-5’ phosphodiester is often replaced by 
phosphorothioate at specific locations of the siRNA sequence to prevent hydrolytic 
degradation. 
3,4
 Various stability studies are routinely conducted during drug product 
development.  The goal of the stability studies is to predict stability performance of the 
product and to inform quality control strategy if chemical degradation is flagged as a 
potential risk.  Forced stress testing is one of the many tools that can be used to predict 
stability problems, develop analytical methods, and help elucidate degradation pathways 
for a new drug candidate. 
5,6
 Stress testing is a systematic study where the molecule of 
interest is deliberately exposed to a series of aggressive conditions to invoke a controlled 
chemical degradation.  The stress study can be performed to probe the intrinsic stability 
of the molecule concerning hydrolysis, oxidation, and photolysis, the three primary 
modes of drug degradation, including RNA. 
7
  The stress testing conditions typically 
include acid, base, hydrogen peroxide, radical initiator (e.g., AIBN or ACVA), light, and 
heat.  The primary degradation products observed under these conditions are known as 
signaling degradation products, as they may form in drug product during long-term 
storage.  Since the signaling degradants present a suitable sample matrix, it can be used to 
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assess HPLC method selectivity towards degradation products in a formulation.  The 
outcome of the stress testing can inform intrinsic stability issues of the molecule and 
provide a scientific framework for a rational selection of excipients for formulation 
development.  While forced stress testing is routinely conducted during formulation 
development for the small molecule-based drug product, few studies have been reported 
in the literature on the use of this predictive tool to evaluate the stability of a chemically 
modified siRNA.  Here we conducted a systematic forced degradation study for a 
synthetic double-stranded siRNA, aiming to probe the intrinsic stability of the molecule 
with respect to hydrolysis and oxidation. 
   
5.2 Material and methods  
 
5.2.1 Chemicals 
The siRNA duplex and the complementary single strands targeting ApoB gene 
were provided by Merck Sharp & Dohme (MSD) RNA synthesis group.   This is the 
same siRNA duplex investigated in Chapter 3.  Triethylammonium acetate, hydrogen 
peroxide (30%), 4, 4′-Azobis (4-cyanovaleric acid) (ACVA), and copper (II) sulfate were 
sourced from Sigma-Aldrich (St. Louis, MO, USA).  HPLC grade acetonitrile as well as 
crystalline Iodine (99%) were obtained from Fisher Scientific.   
 
5.2.2 Instrument  
An Agilent 1290 Infinity UHPLC system (Agilent Technologies, Santa Clara, CA, 
USA) was employed for the separation of siRNA stereoisomers.  This UHPLC system 
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consisted of a binary pump, a diode array detector, an autosampler, and a column heater. 
The system could be operated up to pressure to 1200 bar.   
5.2.3 Ion-pair reversed phase chromatographic conditions 
The siRNA control and stressed samples were analyzed with an ion-pair reversed 
phase UHPLC.  The column was an Acquity BEH C18 (150 x 2.1 mm) with a nominal 
particle size of 1.7 µm.  Mobile phase A consisted of 0.1 M TEAA in water (pH 7), and 
mobile phase B was a mixture of 20% A and 80% organic modifier (ACN).  The gradient 
method was run from 6% to 12% B in 19.5 minutes, followed by steeper gradients of 12% 
to 14%B and 14 to 30%B in 5.5 minutes and 7 minutes, respectively.  
5.2.4  Procedure for forced stress testing 
siRNA was dissolved in 20 mM phosphate buffer solution (pH 7) to approximately  
0.2 mg/mL; aliquots were then subjected to the various stress tests below.   The forced 
degradation study is intended for a qualitative assessment of the chemical stability 
property of the siRNA; hence, it is only performed in a single replicate.  
5.2.4.1 Acid and base stress 
Hydrochloric acid (HCl) or sodium hydroxide (NaOH) was added to separate 
aliquots of the siRNA sample solution to achieve 0.1 M acid or base concentration.  The 
aliquots were stored for 24 hours at room temperature.   The 0.1 M HCl and NaOH were 
chosen as the reactants based on the recommended acid and base degradation conditions 
for small molecule drug products. 
8
 
5.2.4.2 Oxidative stress with hydrogen peroxide  
 A sufficient amount of hydrogen peroxide solution was added to the siRNA 
solution aliquots to achieve a concentration of 0.3 % (v/v).  To evaluate the impact of a 
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transition metal on oxidative degradation by hydrogen peroxide, 1 ppm Cu (II) was 
added to a siRNA solution that contained 0.3% hydrogen peroxide.  The samples were 
stored at room temperature for two and four hours before UPLC analysis.  The 0.3% 
hydrogen peroxide was used for the stress testing of siRNA based on the recommended 
conditions for the oxidative degradation of small molecule drug products. 
8
 
5.2.4.3 Oxidative stress with radical initiator  
4,4′-Azobis(4-cyanovaleric acid) (ACVA) was added to the siRNA solution to 
obtain a final concentration of 5 mM.  This level was used for the stress testing of the 
siRNA based on prior experience from the oxidative degradation study of small molecule 
drug products. 
9
  The siRNA sample containing ACVA was stored at 40 
o
C for 24 hours 
before UPLC analysis.      
5.2.4.4 Desulfurization of siRNA duplex using Iodine  
Iodine solution was used as the oxidizing agent to promote the replacement of 
sulfur by oxygen in phosphorothioate-containing oligonucleotides. 
10
 The reaction was 
initiated by adding 500 µL of 0.03mM iodine solution in ethanol to 4500 µL of the 
siRNA with a molar ratio of about three to one between iodine and siRNA.  The siRNA 
sample solution was analyzed by UHPLC approximately one hour after the iodine was 
introduced.   
 
5.3 Results and Discussion 
 The siRNA duplex targeting ApoB gene is composed of a 21-nucleotide sense 
strand and 23-nucleotide antisense strand (Figure 5.1).  Both sense and antisense strands 
were chemically modified to prevent siRNA degradation due to nuclease-induced 
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hydrolysis.  Specifically, the 2’-hydroxyl groups in seven nucleotides for both strands 
were functionalized with methoxy groups.  In addition, three phosphodiester linkages, 
one from the sense strand and two from the antisense strand, were replaced by a 
phosphorothioate moiety.  A detailed structure was also presented in Figure 3.1a.  Figure 
5.2 shows a typical separation with ion-pair reversed-phase chromatography for double-
stranded siRNA that was denatured on-column.  The sense and antisense strands are well 
resolved from each other, with the sense strand eluting earlier than the antisense strand.  
The sense strand contains one phosphorothioate stereocenter that, together with the 
stereocenters on the ribose sugar, results in one pair of diastereomers as well-resolved 
doublet peaks.  The antisense strand contains two phosphorothioate stereocenters, 
resulting in two pairs of diastereomers, forming four peaks in the chromatogram.   
 The siRNA sample solution was subjected to various stress conditions prior to 
UHPLC analysis.  The chromatograms were compared to the control sample to assess the 
extent of degradation.   
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Figure 5.1 Structure of the ApoB gene-targeting siRNA duplex. Nucleotides marked 
with asterisks contain chemically modified ribose substituents in which the 2’-OH is 
replaced with 2’-methoxy.  In the nucleotides highlighted in red, naturally occurring 
phosphodiester linkages have been replaced with phosphorothioate linkages. 
 
 
 
 
Figure 5.2 A representative chromatogram of siRNA duplex using ion-pair reversed 
phase UHPLC. 
Conditions: UPLC column: BEH C18 (150 x 2.1 mm); Oven temperature: 80 
o
C; Mobile 
phase A consisted of 0.1M triethylammonium acetate (TEAA, pH 7) in water, and 
mobile phase B was a mixture of 20% A and 80% ACN.  The gradient method was run 
from 6% to 12% B in 19.5 minutes, followed by steeper gradients of 12% to 14% B and 
14 to 30% B in 5.5 minutes and 7 minutes.  The flow rate was 0.2 mL/minute and the 
injection volume was 2 µL, with UV absorbance detection at 260 nm.  The siRNA 
sample concentration was approximately 0.2 mg/mL prepared in 20 mM phosphate 
buffer.  
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5.3.1 Chemical stability of siRNA under acid and base stress conditions 
 
 siRNA sample was stressed with 0.1 M HCl or 0.1 M NaOH under ambient 
conditions.  UPLC analysis of the stressed samples showed that siRNA underwent 
significant degradation after 24 hours.  This was to some degree unexpected since we 
predicted that the chemically-modified siRNA should have some resistance to hydrolysis.  
Figure 5.3 shows the overlaid chromatograms of the stressed samples and the control.  
The stressed siRNA in 0.1 M NaOH showed complete drug loss after 24 hours, forming a 
myriad of degradation products with retention times ranging from 2 to 12 minutes.  The 
siRNA sample became slightly hazy upon addition of 0.1 M HCl, and this is likely due to 
the protonation of phosphodiester groups with pKas close to 1. (Scheme 5.1)  The neutral 
siRNA has low solubility in an aqueous medium, which leads to precipitation.  Twenty 
percent methanol was added to the acid-stressed sample to solubilize the precipitates.  
Analysis of the stressed sample showed about 38% (area percentage) of drug loss after 24 
hours in 0.1 M HCl.   
 The acid-mediated degradation pathway of the siRNA is different from that by the 
base; therefore, we anticipated that the acid- and base-stressed samples would exhibit 
distinct chromatographic traces.  Indeed, the degradation product profiles, characterized 
by the retention time distribution, are different between the acid and base stressed 
samples.  While both stressed samples formed degradation products with retention times 
between 2 to 12 minutes, the acid-stressed samples showed another cluster of degradation 
peaks with longer elution times, ranging from 14 to 20 minutes.  The degradation product 
distribution is related to the underlying mechanisms governing the hydrolysis of siRNA.  
A base-catalyzed hydrolysis proceeds with deprotonation of 2’-hydroxyl group by 
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hydroxide to form the nucleophilic 2’-oxyanion.  The attack of 2’-oxyanion nucleophile 
on the tetrahedral phosphate leads to the cleavage of a P-5’O bond of the phosphodiester 
linkage. 
11
 A similar mechanism can be described for the acid hydrolysis, where the 2’-
hydroxy group is the nucleophile attacking the phosphorus, resulting in the cleavage of 
the phosphodiester.  In addition, the RNA can undergo isomerization reaction in the 
presence of an acid with reaction pathway shown in Scheme 5.2. 
12
  Since acid can 
promote both phosphodiester breakage and isomerization, this may explain why the acid-
stressed siRNA has a more complex degradation profile than the base stressed one.    
 siRNA is typically formulated as nanoparticles at pH 7 with lipid or polymer as 
the delivery vehicle; therefore, chemical stability under neutral conditions is more 
relevant for predicting siRNA chemical stability performance during long-term storage.  
Stress testing at pH 7 showed that siRNA is chemically stable after 48 hours at 40 
o
C, and 
the solution is also stable for at least one year when stored at room temperature.   
 
 
 
Figure 5.3 Overlaid chromatograms of the acid or base stressed siRNA and the control 
UHPLC conditions: Same as in Figure 5.2.  
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Scheme 5.1 Deprotonation of a neutral phosphodiester group (pKa approximately 1) 
 
 
 
 
 
Scheme 5.2 Isomerization of RNA in the presence of acid.
12
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5.3.2 Chemical stability under oxidative stress with hydrogen peroxide  
 The oxidation of pharmaceuticals is often attributed to exposure to peroxides.  
RNA oxidative degradation caused by reactive peroxides is well known in the literature. 
13,14
 Residual peroxides can be found in many common excipients for use in oral and 
parenteral formulations. 
15
 Stress testing of the chemically-modified siRNA with 
hydrogen peroxide can be used to probe the oxidative potential of the parent drug and to 
inform excipient selection in support of formulation development.   Here we stressed the 
siRNA sample with 0.3% hydrogen peroxide at room temperature for two and four hours.  
Figure 5.4 shows the overlaid chromatograms of the stressed samples and the control.  
siRNA showed significant reactivity with hydrogen peroxide with approximately 90% 
and 82% parent siRNA loss after 2 and 4 hours, respectively.  Most of the degradation 
products were clustered around the active peak.  Peaks at 17.0, 17.2, 17.6 minutes were 
likely the desulfurization products with oxygen replacing sulfur in the phosphorothioate 
linkage.  Iodine is known to induce a desulfurization reaction in oligonucleotide 
phosphorothioates without incurring other unwanted reaction products. 
16
  Figure 5.5 
shows the overlaid chromatograms of the siRNA samples stressed with hydrogen 
peroxide and molecular iodine.  The oxidation products in the peroxide-stressed siRNA, 
with retention times of 17.0, 17.2, 17.6 minutes, matched with those in the iodine-
stressed sample.  Although hydrogen peroxide induced the desulfurization reaction, its 
underlying mechanism is different from that of iodine.  For hydrogen peroxide, the 
reactive species is likely the hydroxyl radical with the proposed mechanism shown in 
Scheme 5.3. 
17
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 In the hydrogen peroxide stressed siRNA sample, three early eluting degradants 
were also formed with retention time at 1.7, 2.0 and 2.3 minutes.  The formation of the 
early eluting peaks suggested that siRNA underwent significant strand scission (e.g., 
phosphodiester bond breakage) in the presence of hydrogen peroxide. 
 Transition metals, such as Fe (II) or Cu (II), can generate a significant amount of 
hydroxyl radical (OH
.
) with hydrogen peroxide.  The hydroxyl radicals can cause 
efficient degradation of RNA. 
18
 Figure 5.6 showed the overlaid chromatogram of a 
stressed siRNA samples with Cu (II)/H2O2 and the control.  Indeed, siRNA sample 
treated with 1 ppm of Cu (II) and 0.3% hydrogen peroxide led to complete degradation of 
siRNA after 2 hours.  The main degradation products are the three early eluting 
degradants, observed previously in the hydrogen peroxide-stressed siRNA sample.     
 The significant degradation observed for a chemically-modified siRNA, when 
treated with hydrogen peroxide with or without transition metal, is not entirely 
unexpected because the chemical modification is mainly intended for preventing 
hydrolytic degradation.  Given the reactive nature of the chemically-modified siRNA 
towards peroxides, a siRNA-based drug product should not be formulated with 
polyethylene glycol 400 (PEG 400), polyvinylpyrrolidone (PVP), and tween 80 as they 
are known to carry a high concentration of organic peroxides.  The degradation risk 
imposed by the transition metals can be mitigated by incorporating chelating agents, such 
as EDTA, in the formulation.   
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Figure 5.4 Overlaid chromatograms of the stressed siRNA with H2O2 and the control 
UHPLC Conditions:  Same as in Figure 5.2. 
 
 
 
 
Figure 5.5 Overlaid chromatograms of the stressed siRNA with H2O2 or molecular 
iodine. UHPLC Conditions: Same as in Figure 5.2.   
 
 
 
 
Figure 5.6 Overlaid chromatograms of the stressed siRNA with Cu(II)/H2O2 and the 
control.  UHPLC Conditions: Same as in Figure 5.2.   
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Scheme 5.3 Proposed mechanism for desulfurization of phosphorothioate linkage 
induced by hydroxyl radical. 
17 
 
 
 
5.3.3 Chemical stability under oxidative stress with radical initiator 
In addition to peroxide stress, forced stress testing with a radical initiator was also 
performed for siRNA.  4, 4′-Azobis (4-cyanovaleric acid) (ACVA) is an azonitrile radical 
initiator that can thermally decompose to release nitrogen, leaving two cyanoalkyl 
radicals that can rapidly react with oxygen to form peroxy radical. (Scheme 5.4) 
19
  
Peroxy radical promotes oxidation via abstraction of a hydrogen atom from C-H bonds 
with low bond dissociation energy, creating a drug molecule radical that can facilely react 
with molecular oxygen.  Figure 5.7 shows overlaid chromatograms of siRNA stressed 
with ACVA versus molecular iodine.  The oxidation products induced by ACVA are 
exclusively desulfurization products, as the chromatogram (e.g., the retention time of the 
peaks) is identical with that with molecular iodine.  ACVA appears to be more selective 
in forming desulfurization product than hydrogen peroxide.   The oxidative degradation 
pathways mediated by ACVA is different from that by hydrogen peroxide.  While the 
hydrogen peroxide promotes both desulfurization reaction and strand scission, the ACVA 
system exclusively invokes the desulfurization reaction.    
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Scheme 5.4 Thermal decomposition of ACVA to form peroxy radical
19
  
 
 
 
 
 
Figure 5.7 Overlaid chromatograms of siRNA samples stressed with ACVA and 
molecular Iodine.  UHPLC conditions: Same as in Figure 5.2. 
 
 
 
5.4 Conclusions 
 Forced stress testing can be used to probe the main degradation pathway of the 
molecule and provide a rational design for drug product through proper selection of 
excipients.  The stress testing of a chemically modified siRNA showed that the molecule 
is stable at neutral pH.  In contrast, significant hydrolytic degradation was observed under 
extreme acidic or basic conditions.  HPLC analysis showed that the base-stressed sample 
formed more early eluting peaks than the acid-stressed one.  The studies also showed that 
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siRNA is oxidatively labile with respect to hydrogen peroxide.  Desulfurization products 
were detected in the peroxide-stressed sample.  In addition, the hydrogen peroxide 
incurred siRNA strand scission, as evidenced by the formation of early eluting peaks.  
Transition metals, such as copper (II), promote the formation of hydroxyl radical, 
significantly increasing the oxidative degradation of siRNA.  A radical initiator, such as 
ACVA, is a highly selective oxidant and preferentially forms desulfurization products 
with siRNA.  Given the intrinsic stability attributes of siRNA under various stress 
conditions, excipient selection should avoid the use of certain polymers (e.g., 
Polyvinylpyrrolidone (PVP) and PEG) and surfactants (Tween 80) that contain a high 
level of peroxides.  An elevated level of peroxide in PEG and Tween 80 is attributed to 
oxidative degradation of the excipients during storage.   In the case of PVP, residual 
peroxide is the product of a radical-mediated polymerization process used for making the 
polymer.  Control of residual transition metal is also important in the raw material.  The 
degradation risk posed by transition metals can be mitigated by incorporating chelating 
agents, such as EDTA, in the formulation.   
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Chapter 6 Conclusions and future research on the analytical characterization of 
LNPs 
6.1       Conclusions  
siRNA-based therapy has harnessed powerful molecular machinery and 
significantly expanded the target space for drug discovery and development, potentially 
offering new treatments for diseases that cannot be addressed with existing classes of 
drugs.  The systemic delivery of siRNA to target organs or tissues remains a key 
challenge due to various physical and chemical barriers, which can deactivate siRNA 
before it reaches the site of action in a cell’s cytoplasm.  Lipid nanoparticle (LNP) 
delivery technology represents the most advanced platform, with many development 
candidates being tested in human clinical trials.  An LNP system is a complex nanoscale 
assembly, consisting of siRNA, cationic and neutral lipids, including PEGylated lipid to 
maintain physical stability of the nanocarriers.   Developing a stable and high-quality 
LNP formulation not only requires a fundamental understanding of engineering controls 
during the manufacturing process, but it also relies on advanced analytical separation 
tools to ensure that the key constituents in LNPs maintain their potency and purity during 
an intended shelf-life.  Motivated by the significant interest in advancing siRNA 
therapeutics into the marketplace, this research project set out to develop novel 
chromatographic methods capable of separating and quantitating siRNA, lipids, and their 
potential breakdown products due to oxidation or hydrolysis.   
 Synthetic siRNAs often incorporate chemically modified nucleotides to improve 
in vivo serum stability, with the replacement of the phosphodiester linkage by a 
phosphorothioate moiety being a common strategy.  Desulfurization of phosphorothioate-
containing siRNAs compromises the chemical stability of siRNA therapeutics, and it is 
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therefore important to develop a selective separation method to monitor the 
desulfurization of the phosphorothioate-containing siRNAs.  Here a reversed-phase ion-
pairing chromatography method was developed for a baseline separation of multiple 
stereoisomers of a double-stranded siRNA.  With acetonitrile (ACN) as the organic 
modifier, triethylammonium acetate (TEAA) provided a superior separation efficiency 
and selectivity than its structural ion-pair reagent analogs, including ethylammonium 
acetate (EAA), diethylammonium acetate (DEAA) and tetramethylammonium acetate 
(TMAA).  Solution state DSC analysis of siRNA suggested that ACN can effectively 
disrupt the self-association of siRNA double strands, which appeared to be important to 
stereoisomer separation.  This explains why ACN is more effective in stereoisomer 
separation than other organic modifiers, such as methanol.  Other chromatographic 
parameters relevant to diastereomer separation included the chemistry of the stationary 
phase and the column temperature.  The upper temperature limit of the BEH C18 column 
(80 
o
C) was higher than that of the BEH phenyl- and cyano-derivatized silica columns, 
and was an essential condition for the baseline resolution of stereoisomers of the 
denatured siRNA.  The optimized separation method was applied to a siRNA sample 
deliberately stressed with an iodine solution to induce desulfurization, where up to six 
degradation products were resolved from the parent siRNA stereoisomers.    
In addition to the analytical separation of siRNA stereoisomers and their potential 
oxidation products, we also explored ion-pair reversed phase UHPLC for the 
simultaneous separation of siRNA and phospholipids in the context of an LNP delivery 
system, an overlooked need that was previously unaddressed due to the challenge of the 
significant differences in the physical and chemical properties of siRNA and 
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phospholipids.   To reduce the retention gap between these two classes of biomolecules, 
we focused our research efforts on identifying ion-pair reagents that can enhance the 
retention of siRNA, as well as a separation column capable of promoting both 
hydrophobic interactions and π- π interactions between siRNA and the stationary phase. 
With BEH phenyl as the stationary phase and ACN as the organic modifier in the mobile 
phase, dibutylammonium acetate (DBAA) provided a superior separation efficiency and 
selectivity than its structural analogs, such as TEAA, DPAA, and DAAA.  Column 
temperature had a significant impact on the peak shape of double-stranded siRNA, and its 
selection depended on the on-column melting temperature of the siRNA duplex.  The 
method was successfully applied to the separation and analysis of an experimental LNP 
formulation, demonstrating satisfactory selectivity for both siRNA, key constituents in 
lipid vehicles and their respective degradation products.   
 Lastly, a systematic forced stress test was conducted to probe the intrinsic 
chemical stability of siRNA model system using the ion-pair reverse phase UHPLC 
separation developed in Chapter 3.  Forced stress testing is a powerful tool that can 
predict a stability problem during formulation development, assist analytical methods, 
and, by providing a relevant sample matrix, elucidate degradation pathways for a new 
chemical candidate, thus providing a scientific framework for the rational selection of 
key functional excipients.   The stress testing of a model siRNA system showed that the 
molecule is stable with respect to hydrolysis at neutral pH.  In contrast, siRNA is very 
oxidatively labile with respect to hydrogen peroxide, where low-level hydroxyl radical is 
likely the cause for drug degradation.  Desulfurization and phosphodiester strand scission 
are likely the main degradation pathways based on retention behavior of the degradants, 
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as well as by comparison with the iodine-induced desulfurization products.  Transition 
metals, such as copper (II), promote the formation of hydroxyl radical, significantly 
increasing the oxidative degradation of siRNA.  Finally, our studies showed that radical 
initiator, capable of creating peroxy radicals, is a highly selective oxidant that can 
preferentially form desulfurization products.  The instabilities identified in the stress 
testing suggested that the excipients selected should not be comprised of certain polymers 
and surfactants that contain a high level of peroxides.  Furthermore, the degradation risk 
posed by transition metals can be mitigated by incorporating chelating agents, such as 
EDTA, in the formulation.   
6.2 Future research  
 Stereoisomer separation remains a key challenge as the number of sulfur 
modifications is increased to promote greater stability.  Preliminary work on the 
separation of additional siRNAs containing greater than two chiral centers per strand 
showed limited resolution for the stereoisomers using the denaturing ion-pairing UHPLC 
method developed in Chapter 3.  Future work should explore alternative separation 
modes, including ion-exchange chromatography or mixed-mode chromatography that 
incorporates both ion-exchange and ion-pair separation modes.   
 Another potential research area is the direct analysis of free siRNA and the intact 
lipid nanoparticle using columns where the nanoparticles can interact reversibly with the 
stationary phase, i.e., without irreversible adsorption.  Preliminary work using ProSwift 
weak cationic exchange (WAX) monolithic column showed some promising results.  
Figure 6.1 shows the chromatographic traces of the intact lipid nanoparticles and free 
siRNA.  The HPLC analysis requires no sample preparation, and the LNP suspension 
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formulation can be directly injected into the column.  The method could be extremely 
useful in supporting LNP formulation developmental efforts, where the determination of 
encapsulation efficiency of siRNA in LNP is a critical quality attribute for quality 
control.   
 
Figure 6.1 Direct analysis of a LNP formulation: chromatographic traces of intact 
nanoparticles and free siRNA. 
Conditions: Proswift Weak Cationic Exchange column (50 x 4.6 mm); Oven 
temperature: 30 
o
C; Mobile phase A consisted of 10 mM tris buffer (pH 7.2) in water, and 
mobile phase B was a mixture of 10 mM tris buffer and 100 mM NaCl (pH 7.2).  The 
gradient method was run from 65% to 100% B in 10 minutes, followed by an isocratic 
hold at 100% B for 3 minutes.  The flow rate was 0.2 mL/minute and the injection 
volume was 5 µL, with UV absorbance detection at 210 nm.   
  
 Finally, future work in this area should focus on incorporating mass spectrometry 
as alternative detection to UV absorbance in order to fully characterize the main 
degradation products observed in the stress testing presented in Chapter 5.   
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